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ABSTRACT
THE DIETARY ISOPRENOID PERILLYL ALCOHOL INHIBITS TELOMERASE
ACTIVITY IN PROSTATE CANCER CELLS
Tabetha Sundin
Old Dominion University, 2012
Co-Advisors: Dr. Patricia Hentosh
Dr. David Gauthier

This is the first evidence that a plant-derived compound-perillyl alcohol regulates telomerase activity via the mammalian target of rapamycin (mTOR)
pathway in prostate cancer cells.

Telomerase-the enzyme responsible for

immortalizing cells through telomeric repeats addition-is de-repressed early in
an aspiring cancer cell. We hypothesized that perillyl alcohol regulates hTERT
(human telomerase reverse transcriptase) at the translational and posttranslational levels via its effects on the mTOR pathway. A rapid suppression
of telomerase activity was detected in prostate cancer cell lines (PC-3 and
DU145) in response to biologically-relevant concentrations and short
incubations of perillyl alcohol or the mTOR inhibitor-rapamycin.
Western blot analysis revealed a decrease in hTERT protein levels in
response to either agent that did not coincide wholly, with loss of telomerase
activity suggesting a further level of regulation. Using immunoprecipitation we
established the presence of a hTERT-mTOR-S6K (p70 S6 kinase)-Hsp90 (Heat
shock protein 90)-Akt complex previously detected in activated NK cells in
DU145 prostate cancer cells. Further, western blot analysis demonstrated that
perillyl alcohol or rapamycin disrupted the binding interactions between
RAPTOR and hTERT, mTOR, S6K, and Hsp90, establishing an additional
mechanism by which these agents decrease telomerase activity.
Prostate cancer cells overexpress elF4E (eukaryotic initiation factor 4E)
the rate-limiting protein that mediates cap-dependent translation by way of

mTOR signaling.

Immortalized Chinese hamster ovary (CHO) control cells

(pMV7) and CHO cells with forced elF4E-overexpression (rb4E) were used to
elucidate the role of elF4E in telomerase regulation by perillyl alcohol and
rapamycin. Telomerase activity and TERT protein levels were dramatically
attenuated in rb4E cells by perillyl alcohol or rapamycin, but the pMV7 cells
were unresponsive to either agent.

Through western blot analysis we

determined elF4E-overexpression activates Akt-an upstream regulator of
mTOR-through

a

positive-feedback

loop

thereby

increasing

the

phosphorylation of downstream targets of Akt. These findings demonstrate that
elF4E-overexpression in CHO cells alters protein synthetic processes and gene
regulation, thus enabling the inhibitory effects of perillyl alcohol and rapamycin
on telomerase activity and TERT protein levels. This study provides evidence
for a unique link between perillyl alcohol- and rapamycin-mediated regulation of
mTOR and hTERT.
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CHAPTER I
INTRODUCTION, SPECIFIC AIMS AND SIGNIFICANCE

INTRODUCTION
Telomeres
Human telomeres, specialized nucleoprotein structures found at the ends
of chromosomes, consist of a repeated series of the hexameric DNA sequence
(TTAGGG)n, along with a 6-protein complex called shelterin (Fig. 1) [1-3].
Telomeres function to prevent chromosomal degradation and genomic instability
and therefore the loss of genetic information. Although human telomeres are of
heterogeneous lengths, human cells begin with approximately 12 kilobases (kb)
of telomeric DNA; by the time adulthood is reach this number has been reduced
to around 8 kb of telomeric DNA [4], Therefore, telomeres function as molecular
clocks that ultimately link cellular aging to cell division [5]. DNA polymerases
require a double-strand/single strand interface in order to bind DNA and therefore
replicate the strands. The interface is provided by an RNA primer laid down by
an RNA primase. Although only used once at the beginning of replication for the
leading strand, this RNA primer is used repeatedly for the lagging strand. After
DNA polymerase a uses the primer to initiate replication, RNA sequences are
removed, degraded and replaced by DNA. Space becomes limiting at the 3'-end
of the lagging strand, and the RNA primase may no longer bind the strand to
provide an interface. Therefore, DNA polymerase cannot fully replicate the
lagging strand resulting in a single-stranded 3' overhang that will eventually be
cleaved off leading to DNA loss.

The journal format for this dissertation is modeled after Archives of Biochemistry
and Biophysics
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Fig. 1. The shelterin complex,

f ««*TCCC AATCCC AAT C-5"

(a) The six protein complex that constitutes

shelterin. (b) Schematic of shelterin complex bound to a telomere. TRF1 and
TRF2 bind both double-stranded TTAGGG repeats and TIN2. TIN2 also binds
TPP1, which binds POT1.

POT1 binds the single-stranded portion of the

telomere end, creating the D-loop. Reprinted from DNA Repair, 8, Give me a
break: How telomeres suppress the DNA damage response, page 1119, © 2009
Elsevier B.V., with permission from Elsevier. [1].

The inability of DNA polymerase to replicate DNA to the end of the chromosome
is referred to as the 'end replication problem' [6, 7].

The telomeric repeat

(TTAGGG) is non-coding, serving only as a substitute for the loss of
chromosomal DNA that may otherwise occur during replication.
In humans, the protein complex shelterin protects the single-stranded 3'end of the telomere by inducing secondary structure formation. The 3' singlestranded overhang is tucked back into the double-stranded telomeric DNA
creating a t-loop and a D-loop (Fig. 1 (b)) [1, 8]. This secondary structure acts to
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sequester the 3' single-stranded overhang from cellular repair proteins so that it
will not be recognized as a single-stranded break [9], Shelterin is composed of:
telomeric repeat binding factors 1 and 2 (TRF1/2), TRF2- and TRF1-Interacting
nuclear protein 2 (TIN2), protector of the telomere (POT1), the human ortholog of
the yeast repressor/activator protein 1 (RAP)1, and the protein formerly known as
TINT1, PTOP, or PIP1 (TPP1) (Fig. 1 (a)) [10]. Despite the efforts of shelterin,
50-200 bp of telomeric DNA are lost with each round of replication [11], When
telomeres reach a pre-determined critically short length (< 200 bp), the
secondary structure provided by shelterin is disrupted [12]. Through a complex
signaling cascade, the loss of secondary structure provided by shelterin signals
the cells to go into an irreversible state termed senescence [12]. Although the
cell is viable during senescence, it is unable to proliferate.

Without further

damage the cell can remain in the senescent state for long periods of time.
Chromosomes that lack sufficient telomeric repeats are prone to chromosomal
degradation, recombination and fusion events. In this manner, telomeres act as
the protective cap at the end of the chromosome and have been likened to the
plastic tips at the end of a shoelace [13].

Telomerase
The hexameric repeats (TTAGGG)n at the ends of telomeres are
synthesized and maintained by an enzyme called telomerase [14]. Telomerase
is a ribonucleoprotein, consisting of three major components: human telomerase
reverse transcriptase (hTERT), human telomerase RNA component (hTERC),
and the protein dyskerin, all of which are necessary to counteract telomeric
shortening during replication [15-18]. Human TERT is a DNA polymerase that is
also classified as a reverse transcriptase (RT) due to its ability to copy an RNA
template into DNA [15]. Blackburn, Greider and Szostak shared the Nobel Prize
in 2009 for their work with telomeres and their discovery of telomerase. Although
both hTERT and hTERC are necessary for telomerase activation, hTERT is the
catalytic portion of the enzyme and is considered the rate-limiting component [19,
20]. In fact, when the TERT gene is transfected into human cell lines under the
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control of a constitutive promoter, the cells bypass senescence and become
immortal [21]. Three structural components comprise hTERT: a long N-terminus
with DNA and RNA-binding domains, a catalytic reverse-transcriptase domain,
and a short C-terminus extension [22], Similar to most other polymerases, there
are notable fingers, palm and thumb DNA polymerase motifs found in the TERT
protein [23, 24].
The hTERC portion of telomerase enzyme consists of an 11-nucleotide
template core region that provides the RNA template for the enzyme to generate
telomeric repeats [25], In addition to a template region, hTERC has a conserved
region 4 and 5 (CR4/CR5), a pseudoknot motif and the box H and ACA elements
(H/ACA domain) that provide enzyme fidelity, processivity, and are responsible
for the interaction between hTERT and hTERC [26].

Dyskerin, the protein

portion of the telomerase holoenzyme, is necessary for enzymatic regulation.
Current research favors the model of dyskerin along with two ATPases, pontin
and reptin, serving to stabilize hTERC, while hTERC and hTERT assemble.
Although pontin and reptin dissociate, dyskerin remains a part of the active
enzyme [27]. Once all components are together in the complex, telomerase
becomes active and synthesizes telomeric repeats.
Telomerase extends telomeres through a reaction involving cycles of
primer recognition and binding, synthesis and translocation.

Through this

reaction, telomerase adds hundreds of nucleotides to the DNA strand. The first
part of the reaction, primer recognition and binding, is carried out once
telomerase recognizes the 3' single-stranded overhang of the telomere that
serves as the DNA primer for this polymerase [24], Telomerase recognizes the
guanine-rich strand of the telomere as a primer in vivo; it also appears that any
guanine-rich template can serve as a primer for telomerase in vitro [28], During
the synthetic portion of the cell cycle, telomerase processively adds
deoxynucleoside triphosphates (dNTPs) to the end of the telomere, known as
repeat addition processivity. During synthesis, the RNA-DNA hybrid is kept at a
constant length of seven to eight base pairs, due to 5'-bonds melting and 3'bonds being created at the same rate [29].

When the telomerase enzyme
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reaches the 5'-end of the template, it translocates to reposition the DNA at the 3'end of the template to repeat the cycle. The ability of telomerase to add repeats
processively is unique. Most reverse transcriptases are only able to copy an
RNA genome into a single DNA molecule. Telomerase is capable of repeat
addition processivity due to DNA-binding 'anchor sites' that are present in hTERT
[30].

In addition to anchor sites, it has also been shown (in vitro) that the

telomere-binding protein heterodimer TPP1-POT1 stimulates telomerase activity
and processivity, although the mechanism by which this occurs has not been
elucidated [31].
Telomerase and Cancer
Generally, somatic cells and normal cells in culture lack hTERT
expression, so their telomere length continues to shorten with each cell
replication.

Consequently, these telomerase-deficient cells have a limited

number of cell divisions prior to senescence, or a non-replicative state [9], Some
sub-populations of normal human cells do express low levels of telomerase that
are insufficient to achieve immortality.

These include mainly stem cells in

proliferating tissues, germ cells, and activated lymphocytes [32-34], Telomerase
activation or derepression is a critical event in a cell that is progressing towards a
cancerous state [35], Activating/de-repressing telomerase immortalizes ~90% of
cancer cells [36]. The other ~10% of cancer cells activate a mechanism known
as alternative lengthening of telomeres (ALT), in which recombination events
lead to the extension of the telomere [37], Telomerase expression does not
make a cell cancerous, but allows a cell to live long enough to acquire mutations
that increase its likelihood of becoming cancerous. Mouse models have shown
that overexpression of TERT leads to increased tumor formation [38, 39]. This
low level of telomerase is not sufficient to prevent the telomere from shortening,
but it does slow the rate at which the process occurs [40]. Cancer cells have
shorter telomeres than normal cells, sensitizing them to telomerase inhibition
[41]. Therefore telomerase inhibition is an attractive target for cancer therapy.
Telomerase inhibition in cancer cells has been shown to decrease telomere
length and cause cellular senescence or apoptosis, while having little effect on
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normal cells [41]. Telomerase inhibitors thus have a promising role as adjuvant
therapeutics or as chemopreventives [42]. Telomerase inhibition is a key target
for anticancer studies due to the specificity of telomerase expression and the
correlation between telomerase presence and cell immortality.
Telomerase Regulation
The rate-limiting component of the telomerase holoenzyme, hTERT, is
regulated at both the transcriptional and post-transcriptional level. hTERT mRNA
levels are controlled through a series of transcriptional factor interactions with
promoter regions. Posttranscriptional control mechanisms such as structural
changes of the holoenzyme, localization of hTERT, hTERT phosphorylation,
protein degradation and alternative splicing account for a significant degree of
regulation [43],

A critical level of regulation is governed by transcriptional

processes [44], Somatic cells and normal cells in culture do not have detectable
levels of hTERT mRNA, although the RNA component-hTERC-is transcribed and
present at finely regulated levels [19, 45], Eventually normal cultured cells with a
finite number of growth divisions will enter into a stage of growth arrest, termed
senescence.

In time the telomeres of these cells will become so short that the

ends of the chromosomes began to fuse and break. This cellular stage is termed
crisis; all but a few of these cells will succumb to apoptotic death [46], The
limited number of cells that survive crisis become immortalized, a process
characterized by a surge in hTERT mRNA levels [45].

Comparable

transcriptional derepression of hTERT is observed in tumor cells relative to
adjacent normal tissues [45].

The promoter region of the hTERT gene has

multiple binding sites for a vast array of transcription factors (both activators and
repressors), providing clues to the extent of regulatory complexity [47].
Specifically, two Myc/Max binding sites (E-boxes) have been identified in the
hTERT promoter, and c-myc directly activates hTERT transcription [48-50].
Alternatively, Mad-1 can displace Myc and form a heterodimer with Max, thereby
repressing transcription by blocking the E-box found in the hTERT promoter [51].
The human papillomavirus type 16 E6 oncoprotein (E6) also binds the E-box,
thereby activating hTERT [52]. Myc is not the only transcription factor that can
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alter hTERT expression. Estrogen has been shown to activate telomerase via
effects on the hTERT promoter [53].
Adding to the complexity of hTERT transcriptional regulation, signal
transducer and activator of transcription (STAT)3 and STAT5 bind the promoter
of hTERT [54], Telomerase is also upregulated by hypoxia-inducible factor-1
(HIF-1) and via portions of the Ras (rat sarcoma) pathway [55, 56]. Additionally,
leptin, an adipose-secreted hormone, increases the expression of hTERT mRNA
and protein, providing a mechanism of action to explain the increased cancer
incidence in obese patients [57],

Telomerase expression is inhibited

transcriptionally by the p53-mediated binding of the transcription factor, Sp1 [58].
Almost all cancer cells have aberrant Ras signaling and constitutively activated cmyc.

Interestingly, the minimum genetic alterations to induce a fibroblast to

become cancerous include Ras activation, hTERT expression and SV40 large
antigen, which targets the master tumor suppressors, p53 and pRb [59]. Linking
oncogenic pathways to telomerase activation provides a mechanism by which an
aspiring cancer cell can bypass many hurdles simultaneously.
After hTERT transcription has been activated, molecular failsafes still remain
to squelch the pro-cancer activities of a cancer cell apprentice. hTERT mRNA
must be translated and the protein readied for its role. Reversible
phosphorylation of hTERT protein regulates the protein's function, cellular
localization and ultimately telomerase activity [60],

Human TERT is

phosphorylated by more than one kinase at different sites in the protein. A welldescribed relationship between hTERT and a kinase is the association between
hTERT and Akt (also known as protein kinase B). Akt is an important protein in
the phosphatidylinositide-3 kinase (PI3K)-Akt-mammalian target of rapamycin
(mTOR)

signaling pathway

that governs

protein translation.

Akt,

a

serine/threonine kinase, phosphorylates hTERT at Serine 824 (Ser 824) and
Serine 227 (Ser 227) [61]; phosphorylation of either site upregulates telomerase
activity. Protein kinase C (PKC) has also been to shown to induce hTERT
expression and modulate its activities post-transcriptionally by phosphorylation
[36, 62],
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Likewise, hTERT phosphorylation is important in the nuclear localization of
the protein where it may join hTERC and activate the telomerase holoenzyme
[63]. Human TERT can only bind its nuclear translocator, nuclear factor (NF)-KP,
in its phosphorylated form [64, 65],

Upon localization in the nucleus,

phosphorylated hTERT binds 14-3-3 signaling proteins that act to sequester
hTERT in the nucleus where it may associate with the other components of the
telomerase holoenzyme to perform its function to extend the telomeres [66],
Tumor cells with high levels of telomerase activity contain phosphorylated forms
of hTERT that are found mainly in the cell nucleus [67, 68], Conversely, protein
phosphatase 2 A (PP2A) abrogates telomerase activity by dephosphorylating the
protein. This maybe a direct dephosphorylation event or alternatively it could be
a downstream effect of PP2A dephosphorylating Akt rendering it incapable of
phosphorylating hTERT [69-71]. Heat shock protein 90 (Hsp90), a protein known
to associate with both hTERT and Akt, also has an important role in telomerase
activity. Hsp90 prevents PP2A from dephosphorylating Akt [69]. Further, Hsp90
is necessary for assembly of the telomerase holoenzyme, and is itself regulated
through phosphorylation [72]. Reactive oxygen species (ROS) have been shown
to induce phosphorylation of hTERT Tyrosine 707 (Tyr707) via Src (sarcoma)
kinase [73].

Tyr707 phosphorylation has the opposite effect of that observed

with Ser824 phosphorylation; this event is critical for hTERT nuclear export,
translocation back into the cytoplasm and loss of telomerase activity. Thus,
nuclear localization is another level in the multistep regulation of telomerase
activity.
Human TERT protein levels are additionally regulated through the actions of
the ubiquitin-protein ligase (E3 ligase) Makorin-1 (MKRN1) [74],

MKRN1

recognizes hTERT and targets it for degradation via the ubiquitin-26 S
proteasome pathway (UPS).

Hsp90 is thought to rescue hTERT from

degradation by preventing the actions of MKRN1 [74]. While the mechanism is
not understood currently, the association of Hsp90 with hTERT may prevent
MKRN1 from recognizing hTERT as a substrate. MKRN1 levels dramatically rise
when a cell enters the G1 state of the cell cycle, providing a possible link
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between telomerase activity and the cell cycle [75]. Although MKRN1 is the only
E3 ligase that has been identified currently, there may be other E3 ligases that
target hTERT for degradation.
Non-Telomeric Functions of Telomerase
In addition to providing a cell with immortality, telomerase has a much larger
role in cancer development. When hTERT is overexpressed in a variety of cells,
the cells become resistant to apoptosis [76-79]. In fact hTERT blocks both the
intrinsic and extrinsic apoptotic pathways [80-82], and is itself a target for
caspase-6 and caspase-7 cleavage [83].

The mechanism by which hTERT

blocks apoptosis is unclear; however it appears to inhibit an early step in the
apoptotic pathway prior to caspase activation [84],
Besides the anti-apoptotic functions of hTERT, telomerase is involved in
multiple levels of DNA repair. hTERT and hTERC both have a role in regulating
the ATM (ataxia telangiectasia mutated)-ATR (ataxia telangiectasia and Rad3related kinase) DNA damage pathway. hTERT upregulates ATM causing cell
cycle arrest to allow DNA repair or apoptosis [85]; hTERC inhibits ATR, thereby
preventing cell cycle arrest [86]. Cells that overexpress hTERT have 20-fold less
spontaneous chromosome breaks and increased levels of ATP, possibly due to
increased mitochondrial DNA protection [87],

Many of the DNA damage

response factors are dependent on ATP hydrolysis, including chromatin
decondensation responsible for activating ATM, which results from a doublestrand break [88, 89]. Telomerase repairs these double-strand breaks by the de
novo addition of telomeres in a process termed 'chromosome healing' [90], This
extends the life of a cell with a defective genome, thus increasing the possibility
of that cell becoming cancerous.
Ectopic hTERT expression further revealed that hTERT is responsible for
regulating nearly 300 genes that participate in functions such as cell cycle
progression, apoptosis, metabolism and signaling [91]. Further, hTERT has been
implicated in pRb hyperphosphorylation, causing unchecked cell cycle
progression and providing a growth advantage for hTERT-overexpressing cells
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Fig. 2. Proposed schematic representation of the hTERT-mTOR-RAPTOR
complex in DU145 prostate tumor cells. The presence of mTOR in a complex
with TERT provides compelling evidence for the mTOR-mediated control of
telomerase activity. The arrows represent phosphorylation of the substrates
by mTORCI.

[92-94], Additionally, hTERT is responsible for the transcriptional activation of
cyclin D1 [95],
The cancerous phenotype associated with hTERT-overexpressing cells is
exacerbated by the ability of hTERT to upregulate epidermal growth factor
receptors (EGFRs) [96], EGFRs are responsible for multiple oncogenic signaling
pathways. Increased numbers of cell surface receptor sensitizes a cell to low
levels of growth factors.

Thus under conditions of limited growth factors,

signaling pathways deceive the cell that nutrients are ample. Cancer cells are
known for their ability to survive in low nutrient environments by usurping EGFR
signaling pathways.
mTOR
Hsp90, Akt, hTERT, p70 S6 kinase (S6K), and mTOR form a physical
complex with one another (Fig. 2) [70],

This complex provides compelling

evidence mTOR-mediated control of telomerase activity.

Through kinase

cascades, mTOR regulates cell size, progression of the cell cycle, and cell
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survival, arid is considered a master regulator of protein synthesis [97], mTOR, a
serine/threonine kinase that is often dysregulated in cancer cells, is a member of
the PI3K-related kinase (PIKK) family [98]. By nucleating two different functional
multi-protein complexes, mTOR complex 1 (mTORCI) and mTOR complex 2
(mTORC2), mTOR responds to nutrient, energy and oxygen stresses on the cell
[99, 100].

The best characterized of these is the the mTORCI homodimer

complex that consists of mTOR, accessory protein RAPTOR (regulatoryassociated protein of mTOR), mammalian lethal with Sec13 protein 8 (mLST8)
(also known as G|3L), PRAS40 (proline-rich AKT substrate 40 kDa), and DEPdomain-containing mTOR-interacting protein (DEPTOR) (Fig. 3) [99]. mTOR can
alternatively associate with the complex involving RICTOR (rapamycininsensitive companion of mTOR), mLST8, DEPTOR, PROTOR (protein observed
with RICTOR), and mSIN1 (mammalian stress-activated protein kinase
interacting protein); this complex is termed mTORC2 (Fig. 3) [99]. In addition to

mTORCI

mTORCI

Fig. 3. Schematic representation of the mTORCI and mTORC2 complexes.
mTOR is known to nucleate two distinct protein complexes. The mTORCI
complex consists of mTOR, RAPTOR, PRAS40, DEPTOR, and mLST8.
mTORC2 consists of mTOR, RICTOR, mSIN1, DEPTOR, PROTOR, and
ml_ST8.

Despite having a few proteins in common, these complexes are

known to behave very differently from one another.
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being necessary for the catalytic activities of mTOR, both RICTOR and RAPTOR
help to recruit downstream targets to the complex [101]. mTORCI, touted for its
nutrient sensing abilities, is associated with the predominant pathway by which
mTOR controls cell growth and proliferation, the PIK3-Akt-mTOR pathway. It is
now understood that mTORC2 has a role in this pathway by activating Akt
through phosphorylation, creating a positive feedback loop [102], mTORC2 is
also known for its ability to direct actin remodeling [100]. The well-established
functions of mTOR are due to mTORCI, as mTORC2 functions are just now
beginning to be elucidated [103].
Upstream Regulation of mTOR
The PI3K-Akt-mTOR pathway is an important mechanism that allows
communication between cellular and intracellular proteins responsible for growth
and proliferation. When insulin binds its receptor on the cell membrane surface,
a kinase cascade is initiated.

The binding event signals insulin receptor

substrate 1(IRS1) to the intracellular portion of the receptor [104], IRS1 then
activates the first kinase in this pathway, PI3K, which recruits Akt to the
intracellular portion of the cell membrane [104-107].

Akt is then activated

through both phosphoinositide-dependent protein kinase I (PDK1) and mTORC2.
Akt in turn phosphorylates the GTPase activating protein (GAP)-tuberous
sclerosis 2 (TSC2)-thereby deactivating the protein. In the absence of a growth
factor such as insulin, the active TSC2 forms a complex with TSC1 that
accelerates the exchange of Rheb (Ras homolog enriched in brain)-GTP
(guanosine triphosphate) to Rheb-GDP (guanosine diphosphate). Rheb must be
in the GTP form in order to directly stimulate mTORCI [104, 105].

As a

consequence of Akt phosphorylation, TSC2 is deactivated, thereby allowing
mTORCI activation through Rheb-GTP. Akt also phosphorylates PRAS40, an
inhibitor of mTORCI, therefore deactivating it [108].

Although PRAS40 is a

known binding partner of mTORCI, in the absence of insulin, PRAS40 functions
to inhibit Rheb activation of mTORCI [108].

13
Translational Control: Regulation of elF4 and p70 S6 Kinase

Fig. 4. The mTOR pathway. mTOR is considered a master regulator of
protein translation. This pathway depicts the numerous proteins upstream
and downstream of mTOR, which ultimately determines when capdependent translation is turned on or off. Illustration from Cell Signaling
Technology, Inc., 2003-2010.

Down-stream Targets of mTOR
Mitogenic activation of mTORCI increases cap-dependent translation
initiation through phosphorylation of S6K and 4E-binding protein 1 (4E-BP1) (Fig.
4). mTORCI activates S6K through the phosphorylation of specific sites on the
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protein. Only the active or phosphorylated form of S6K can act as a kinase and
phosphorylate S6, a ribosomal protein. S6 activation is necessary for translation
of ribosomal proteins.

Through a negative feedback loop, S6K also

phosphorylates IRS1, therefore deactivating the protein necessary to initiate
PI3K-Akt-mTOR pathway [109]. S6K also activates eukaryotic initiation factor
(elF) 4B, a protein responsible for activating elF4A, a helicase necessary to
unwind the 5' untranslated region (UTR). In addition, S6K inhibits programmed
cell death protein 4 (PDCD4), a protein that inhibits elF4A [110]. mTORCI also
acts as a kinase that directly phosphorylates 4E-BP1, an inhibitor of translation,
resulting in dissociation of elF4E. This allows the mRNA cap-binding protein to
associate with the scaffold protein elF4G [111]. The association of activated
elF4A with elF4E and elF4G completes formation of the 7-methylguanosine
triphosphate (m7GpppX) cap-binding complex termed elF4F [112]. Binding of
elF4F to the 5' cap of mRNA is followed by circularization of the mRNA, a
process that occurs via interactions between elF4G and the poly-A binding
protein (PABP) [113].

The 43S complex, consisting of the 40S ribosomal

subunit, elF2/GTP/Met-tRNAi, and elF3, binds to elF4F via interactions between
elF3 and elF4G forming the preinitiation complex [111].

This complex begins

scanning the mRNA in a 5' to 3' direction from the mRNA cap.

Once a

translation initiation codon or AUG with the optimal consensus sequence is
located, the pre-initiation complex is released and an initiating methionine is
inserted into the aminoacyl site formed by association of the 60S ribosomal
subunit with the 40S ribosomal subunit to form an 80S ribosomal complex.
Subsequent elongation of the protein occurs though translocation of the nascent
peptide to the peptidyl site of the 80S complex and formation of peptide bonds
[111].
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Fig. 5. How cellular stressors regulate mTOR activation. Activation of mTOR
by growth factors is depicted as a black line. mTOR inhibition by a protein is
depicted by a grey line. Pathways that have not been confirmed as a direct
association between the protein and mTOR is shown as a dotted line.

Importantly, elF4E is the rate-limiting component of the translation initiation
complex [114]; its release from 4E-BP1 due to mTORCI activation, controls
protein translation. mRNAs with 5'-UTRs that are G-C rich have substantial
secondary structure, and cannot compete for elF4E as well as mRNAs without
stable 5-UTR secondary structure [115-117]. Consequently, free elF4E levels
are tightly regulated through mitogenic activation of the mTOR signal
transduction pathway [118]. Due to the ability of mTORCI to inhibit an inhibitor
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(4E-BP1) and activate a protein crucial to translation initiation (S6K), mTORCI is
a master regulator of protein synthesis [119].
In addition to its well-established function in modulating translation initiation,
mTOR is responsible for cell growth regulation, transcriptional control, and
autophagy repression [105].

mTORCI mediates cell cycle regulation by

increasing elF4E levels sufficiently to initiate cap-dependent translation of cyclin
D1 mRNA [120]. Conversely, in cells where mTORCI is inactivated, translation
initiation of cyclin D1 mRNA is suppressed sufficiently to arrest the cell in G1
[120]. The mTORCI pathway also controls cell size and glucose homeostasis
apparently through the activation of S6K, although the mechanisms are not yet
clear [121]. S6K activation also increases the levels of survivin, an inhibitor of
apoptosis [122], mTOR-mediated autophagy repression is a result of a direct
interaction of mTOR with the ULK (Unc-51-like kinase 1) complex necessary to
initiate autophagy [105], With assorted downstream targets of mTOR whose
activation or repression can result in either survival or cell death, it is imperative
to properly regulate the mTOR pathway to preserve normal cellular homeostasis.
Cellular mTOR Inhibition
Diverse cellular stressors inhibit the mTOR pathway through various
mechanisms (Fig. 5) [97],

Protein translation occurs at a high adenosine

triphosphate (ATP) cost for the cell. Therefore, shutting it down when the cell is
stressed is imperative. DNA damage is one such cellular stress that activates
both p53 and Redd1/RTP01 [123]. Through downstream signaling, both of these
proteins activate TSC 1/2 and inhibit mTOR via Rheb [124], Hypoxia is a well
characterized stressor that signals activation of BCI2/adenovirus E1B 19 kDa
protein-interacting protein 3 (BNIP3), promyelocytic leukemia tumor suppressor
(PML), and Reddl via induction of HIF-1 [125].

BNIP3 inhibits Rheb

independently of TSC 1/2; PML directly inhibits mTOR [125],

Hypoxia and

glucose derivation lead to low ATP, a signal that activates 5'AMP-activated
protein kinase (AMPK) [126]. AMPK inhibits mTOR directly and activates TSC
1/2 [126],

Glucose deprivation is third type of stress that activates Reddl,

making Reddl a critical activator of TSC 1/2. Interestingly, it has been shown
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that cigarette smoke can also induce Reddl [127].

Amino acid deprivation

inhibits two activators of mTOR, GTPase Rag (Ras related GTPase) and Map4k3
(mitogen-activated protein kinase kinase kinase kinase 3) [128], When active,
Rag serves to bind RAPTOR and translocate mTORCI to the surface of an
endomembrane compartment, serving along with Rheb to activate mTORCI
[129]. The redundancy in pathways mediating mTOR inhibition highlights the
importance of maintaining protein only under ideal cellular conditions.
mTOR and Cancer
The mTOR pathway is often constitutively active in cancer cells, leading to
aberrant protein translation, cell growth, and proliferation. The tumor suppressor,
phosphatase and tensin homolog (PTEN), is commonly deleted or truncated in
endometrial, breast, prostate and ovarian cancers leading to overexpression of
the PI3K-Akt-mTOR pathway [130], A commonly observed mutation in PIK3CA
in breast, colorectal, and endometrial cancers results in overexpression of Akt
and increased transformation in vitro and in vivo [131]. The AKT1 gene may also
be amplified causing it to be overexpressed in some tumor cell types. AKT1
mutations have been shown to constitutively activate the protein, as seen in
some breast, colorectal and ovarian cancers [132-134], Enhanced expression of
the downstream target of mTORCI, elF4E,

by gene amplification is also

regularly observed in tumor cells, leading to increased protein translation [135],
elF4E-overexpression is an independent biomarker of cancer recurrence in head
and neck cancers [136], The array of mutations identified that lead to mTORCI
pathway upregulation in numerous diverse cancers support the role of mTOR as
an attractive anti-cancer target.
Rapamycin
The classical mTOR inhibitor is the macrolide antibiotic, rapamycin (Fig. 6
(a)). The vast array of mTORCI functions were revealed through the use of
rapamycin. Rapamycin was discovered in Streptomyces hygroscopicus in the
soil on Easter Island in the 1970s [137]; it was not until the 1990s that the cellular
target of this drug, mTOR, was uncovered [99], Rapamycin binds to the 12 kDa
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immunophilin FK506-binding protein (FKBP12), forming a drug-receptor complex,
which then binds to mTOR.

This process weakens the association of mTOR

with RAPTOR, thus inhibiting the kinase activity of mTOR [138-140]. Although
mTORC2 is considered rapamycin-insensitive, it has been shown that prolonged
treatment with rapamycin does inhibit mTORC2 assembly [141].
Cellular treatment with rapamycin causes decreased phosphorylation of 4EBP1, therefore reducing the level of free elF4E for translation initiation [142],
Rapamycin likewise attenuates the phosphorylation of S6K and S6 ribosomal
protein [142]. It has been shown that rapamycin at 10 nM at 4 hr, a clinically
relevant concentration [143], is capable of inhibiting the mTORCI pathway, thus
impeding cellular proliferation, growth and translation initiation [144, 145],
Analogs of rapamycin ('rapalogs') have been approved for use in several forms
of metastatic cancers and continue to be evaluated in Phase III solid tumor
studies.
An mTOR and telomerase liaison
An association between mTOR and telomerase activity was first proposed
by Zhou et al. (2003) and later by Zhao et al. (2008) who noted that rapamycin,

(b)

(a)

.OH
O OCH;

Fig. 6. Biochemical structures of rapamycin and perillyl alcohol, (a)
Rapamycin; (b) Perillyl alcohol. www.SigmaAldrich.com
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at high concentrations (100 - 1000 nM) and long treatment conditions (48 to 72
hr), inhibited both telomerase activity and hTERT mRNA levels [146, 147].
Effects on hTERT mRNA levels were somewhat surprising based on the known
cellular target of mTOR—protein translation. It should be pointed out that the
maximum tolerated dose of oral rapamycin administered to adult cancer patients
on a daily basis has been reported at ~6 mg/d, which results in a maximal
plasma concentration of ~22 nM [143],

hTERT co-immunoprecipitates with

mTOR, S6K, Hsp90 and Akt, suggesting that these proteins form a physical and
functional complex [70].

Bu et al. also proposed in 2007 [148] that mTOR

signaling was 'coupled' to telomerase regulation. In contrast to the above two
studies, Bu et al. showed that rapamycin (10 nM) had no effect on the hTERT
promoter, but that hTERT protein levels were decreased; they concluded that
hTERT regulation by rapamycin was post-transcriptional [148]. Researchers and
clinicians may be able to take advantage of this relationship between mTOR and
telomerase for effective combination therapy and/or cancer chemoprevention.
Bu et al. (2007) also noted synergy in regards to down-regulation of telomerase
activity between rapamycin and fluorouracil treatment of hepatocarcinoma cells
in culture [148],
In addition, because telomerase activation/de-repression is an early event
in cancer cell formation, the ideal chemopreventive would be present and active
before cancer is detectable. Rapamycin itself has been touted as a new potent
cancer chemopreventive agent [149, 150], but grave concerns about toxic side
effects (immunosuppression), safety (feedback activation of Akt and enhanced
tumorigenesis) and pharmacokinetic issues temper enthusiasm for this approach
[151, 152].

The potential effectiveness of plant-derived dietary factors with

relatively low acute toxicity [153] contrasts to that of rapamycin; consequently
phytochemicals may represent a more feasible and effective method for cancer
prevention. As described below, isoprenoids have been reported to modulate
either mTOR signaling or telomerase activity. These data reported in this study
collectively form the basis of our proposal that mTOR and telomerase regulation
are coupled.
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Isoprenoids
Isoprenoids (also designated as terpenes), found widely in fruits and
vegetables, represent the largest group of natural products with -25,000
structures reported [154, 155], and are recognized for their ability to suppress
carcinogenic processes in vivo and in vitro [153, 156-158].

Isoprenoids are

small, lipophilic products of the plant mevalonate biosynthetic pathway [153],
Isoprenoids are so-named because of their basic chemical structure consisting of
multiples of an isoprene (5-carbon) subunit: monoterpenes consist of C10,
sesquiterpenes, C15; diterpenes, C20 and others. In plants they function as
repellents, attractants or toxins, and provide resistance to aphid infestations or
fungal- and bacterial-caused diseases [154], Isoprenoids are relatively non-toxic
in human studies even at high doses [159],
Perillyl alcohol, a structurally simple monoterpene, is found predominantly in
oils from cherries, cranberries, lavender, celery seed and spearmint (Fig. 6 (b))
[79, 160],

Perillyl alcohol and other related terpenes, such as farnesol and

geraniol, exhibit chemopreventive and cytotoxic activity against a wide variety of
cancer cell lines [153, 156, 158, 161], Perillyl alcohol was found to act uniquely
and mechanistically on protein translation through modulation of mTOR signaling
pathway [145]. It specifically decreases 4E-BP1 phosphorylation and disrupts
the elF4F 5'- cap-binding complex [144, 145]. While perillyl alcohol has been
shown to suppress the mTOR pathway, the mechanism appears to be distinct
from that for rapamycin. In addition to the mTOR pathway, perillyl alcohol has
the ability to inhibit other pathways associated with the cancer phenotype, such
as cell growth, pRB phosphorylation and Cdk phosphorylation [162-165]. Perillyl
alcohol can also counteract proliferation and initiates apoptosis and G1 arrest
[165-170], Although a small, natural compound, perillyl alcohol is becoming wellestablished as a cancer chemopreventive agent [153, 158].
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Rationale of Study and Specific Aims
Prostate cancer is a leading cause of cancer death among men, second
only to lung cancer. One in six males will be diagnosed with prostate cancer
during their lifetime, with no effective cure available for those with advanced
stages of the disease. hTERT, the limiting factor for telomerase activation, is derepressed in prostate cancer cells and in part makes these cells immortal. It has
been reported that hTERT forms a functional complex with mTOR, S6K, Hsp90
and Akt in activated natural killer cells (NK). mTOR is a master regulator of
protein translation through its ability to release the rate limiting component of
cap-dependent translation, elF-4E, from 4E-BP1. The presence of mTOR in
association with hTERT strongly signifies mTOR's involvement in regulating
telomerase activity. The macrolide rapamycin effectively treats hormone-related
cancers through its modulation of the mTOR pathway.

A plant-derived

isoprenoid perillyl alcohol also suppresses mTOR signaling; its mechanism of
inhibition appears to be similar but distinct from that for rapamycin.

Perillyl

alcohol is potentially more effective at preventing prostate cancer than is
rapamycin due to its small size, lipophilic nature and relatively low toxicity.
Recent studies have shown that rapamycin at high concentrations and long
incubations inhibits telomerase activity and hTERT mRNA levels. Currently, it is
unknown if perillyl alcohol also modulates telomerase activity.

Thus perillyl

alcohol may be important clinically due to the documented immunosuppressive
toxicity of rapamycin in cancer patients.

Therefore, perillyl alcohol-mediated

inhibition of hTERT represents a potential cancer chemopreventive or adjuvant
for therapy.
Our long-term goal is to understand the mechanism by which isoprenoids
are effective as chemopreventives. The objective of this research is to explore
the relationship between perillyl alcohol, telomerase function and the mTOR
pathway. The central hypothesis is that perillyl alcohol regulates hTERT at the
translational and post-translational levels via its effects on the mTOR pathway.
The hypothesis is supported by studies demonstrating similarity between the
mechanisms of action of rapamycin and perillyl alcohol, and the known inhibitory
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relationship between rapamycin and telomerase activity.

The rationale

supporting the proposed research is that elucidating novel mechanisms by which
perillyl alcohol inhibits prostate cancer cell proliferation will enhance exploitation
of this agent as a chemopreventive for prostate cancer. The central hypothesis
will be tested and the objective of this proposal met through the following three
specific aims:
Specific Aim 1. Establish the translational and post-translational effects of
perillyl alcohol treatment on hTERT regulation in cultured human
prostate cancer cells. Specifically, DU145 and PC3 cells will be treated
with solvent, perillyl alcohol or rapamycin as a positive control, and:
A. Telomerase activity assessed using real-time polymerase chain
reaction telomeric repeat amplification protocol (RTQ-TRAP) as
well as non-denaturing polyacrylamide gel electrophoresis (PAGE);
B. SDS/PAGE and western blots performed to detect potential
modulation of hTERT protein levels, phosphorylation status, cellular
location and degradation; and
C. Co-immunoprecipitation with a RAPTOR or mTOR antibody, silver
stained gel analysis, and western blots carried out to establish the
presence of co-precipitating proteins in the hTERT-mTORRAPTOR protein complex in untreated cells and possible disruption
of the complex by perillyl alcohol and/or rapamycin.
Specific Aim 2. Define the transcriptional effects, if any, of perillyl alcohol
treatment on hTERT regulation in prostate cancer cells. DU145 and
PC3 cells will be treated with solvent, perillyl alcohol or rapamycin as a
positive control, and:
A. Real-time reverse transcriptase-polymerase chain reaction (real
time RT-PCR) utilized to measure isoprenoid effects on hTERT
mRNA levels.

3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-

CoA) reductase mRNA will be included as a control; results will be
interpreted using the AA Ct method.
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Specific Aim 3.

Examine telomerase activity, TERT mRNA and TERT

protein levels in cells that over-express eukaryotic initiation factor 4E
(elF4E)-the rate-limiting factor for cap-dependent translation regulated
by mTOR.

Immortalized Chinese hamster ovary (CHO) cells

transfected with an e/F4£-expressing vector or a control vector will be
treated with solvent, perillyl alcohol or rapamycin as a positive control
and:
A. SDS/PAGE and western blots performed to study the effect of
elevated elF4E on TERT, Akt, S6K, and 4E-BP1 protein levels and
the phosphorylation status of Akt, S6K, and 4E-BP1;
B. Real-time RT-PCR conducted to assess the consequence of
amplified elF4E on TERT mRNA. Actin mRNA will be included as a
control; and
C. RTQ-TRAP exploited to measure alterations in telomerase activity
when elF4E is over-expressed.

SIGNIFICANCE
The proposed research is innovative, because a relationship between
telomerase activity, hTERT and perillyl alcohol has not been explored or
exploited previously.

Our study is projected to first: identify and establish a

translational and/or post-translational inhibitory relationship between perillyl
alcohol and hTERT. This finding will allow us to determine the mechanism by
which perillyl alcohol can be used as a cancer chemopreventive. Secondly, we
expect to find that perillyl alcohol down-regulates hTERT through the mTOR
pathway. With this knowledge perillyl alcohol may be used as an adjuvant to
current chemotherapy regiments that do not target the mTOR pathway. By using
a biologically relevant concentration of rapamycin for a reasonable period of time
as a control, we will be able to determine the direct effects of mTOR inhibition on
telomerase activity. The expected outcomes are foreseen to have an important
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positive health impact because these findings will lead to novel cancer
therapeutics/adjuvants and greatly advance the field of chemopreventives.
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CHAPTER II
THE ISOPRENOID PERILLYL ALCOHOL INHIBITS TELOMERASE
ACTIVITY IN PROSTATE CANCER CELLS

INTRODUCTION
Nutritional epidemiologists emphasize that diet has a major role in the
incidence and progression of prostate and other types of cancer [39, 153, 158,
171].

Isoprenoids (also referred to as terpenes), found widely in fruits and

vegetables, represent the largest group of naturally occurring organic chemicals
with ~25,000 structures reported [155], and are recognized for their ability to
suppress carcinogenic processes in vivo and in vitro [172]. Perillyl alcohol is a
small lipophilic isoprenoid found predominantly in oils from cherries, cranberries,
lavender, celery seed and spearmint [79, 160], Perillyl alcohol and other related
terpenes, such as famesol and geraniol, exhibit chemopreventive and cytotoxic
activity against a wide variety of cancer cell lines [153, 156, 158, 161].
Additionally, perillyl alcohol alone or included as an adjuvant inhibited various
tumor xenografts in mouse models including human pancreatic cancer cells [172175]. Previous studies in our lab demonstrated that perillyl alcohol acts uniquely
and mechanistically on protein translation through modulation of the mammalian
target of rapamycin (mTOR) signaling pathway [145],
mTOR, a serine/threonine protein kinase, is a critical component of the
phosphoinositide 3-kinase (PI3K)/Akt pathway.

Through kinase cascades,

mTOR regulates cell size, progression of the cell cycle and cell survival [119],
mTOR protein exists in two functional complexes: mTORCI and mTORC2.
mTORCI regulates protein translation through phosphorylation and activation of
p70 S6 kinase (S6K) and 4E-binding protein 1 (4E-BP1). Only the active form of
S6K can subsequently phosphorylate S6, a ribosomal protein, which is
necessary for ribosome assembly and protein translation. Phosphorylation of
4E-BP1, an inhibitor of translation, causes it to dissociate from eukaryotic
initiation factor 4E (elF4E) allowing translation to begin. Due to its ability to
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inhibit an inhibitor (4E-BP1) and activate a protein crucial to translation initiation
(S6K), mTORCI is a master regulator of protein synthesis [119].
The classical mTOR inhibitor is the macrolide, rapamycin. Rapamycin
treatment causes decreased phosphorylation of 4E-BP1. Unphosphorylated 4EBP1 binds elF4E efficiently and reduces cellular levels of elF4E available for
formation of the m7GpppX cap-binding complex-elF4F. Rapamycin likewise
reduces the phosphorylation of S6K and S6 ribosomal protein [142]. Perillyl
alcohol displays similar properties to rapamycin, but is distinct, in that it
suppresses 4E-BP1 phosphorylation in human prostate and colon tumor cells via
mTORCI, with a similar or greater effect than that observed with rapamycin as
detected by western blotting [144, 145],

Perillyl alcohol also disrupts the

m7GpppX cap binding complex, elF4F, by suppressing interaction of elF4E with
elF4G [144, 145],
Recently, both mTOR and S6K were found to co-immunoprecipitate with
human telomerase reverse transcriptase (hTERT), Hsp90 and Akt suggesting
that these proteins form a physical and functional complex [70], hTERT is one of
three components of telomerase, a ribonucleoprotein complex responsible for
adding 6 base pair (bp) repeats to the end of a chromosome to prevent loss of
DNA during replication.

This action is necessary due to the fundamental

limitation of polymerization at chromosome ends.

hTERT, the rate limiting

enzymatic portion of telomerase, is a potential candidate for cancer therapy due
to its absence in most normal somatic cells, but its re-activation in many tumor
cells. Telomerase activation is an early and key event in the creation of tumor
cells, and as such, is an important target in cancer prevention. The inclusion of
mTOR and S6K in the hTERT complex is compelling evidence to support mTORmediated control of telomerase activity, and as such, we hypothesize that
isoprenoids, such as perillyl alcohol, suppress telomerase activity. The effects of
perillyl alcohol on telomerase activity are examined in this work.
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MATERIALS AND METHODS
Cell lines and cell culture
Human prostate cancer cell lines PC3 and DU145 (American Type Culture
Collection, Manassas, VA) were maintained at 37°C in a humidified incubator
with 5% C02 in RPMI-1640 medium supplemented with 10% fetal bovine serum,
1X glutamine and 1X penicillin/streptomycin. Growth medium was changed every
other day.
Drug treatments
Perillyl alcohol (Sigma-Aldrich, St. Louis, MO) was prepared in 100%
ethanol; rapamycin (Cell Signaling Technology, Danvers, MA) was dissolved in
100% dimethyl sulfoxide (DMSO) [145], PC3 and DU145 cells were plated at a
concentration of 5x105 cells per 60 mm plate in 3 mL medium and allowed to
attach overnight.

Cells were then treated with one of the following: 400 pM

perillyl alcohol for 16 hr, 10 nM rapamycin for 4 hr, 0.1% DMSO for 4 hr or 0.1%
ethanol for 16 hr as described by Peffley et al. [145]. In separate experiments,
shorter incubations with either drug were also conducted to establish a time
course of possible effects.
Protein extraction for telomerase activity
Cells were harvested using trypsin-EDTA (Gibco/lnvitrogen, Carlsbad, CA)
and then pelleted by centrifugation (500 x g) for 8 min. Cell pellets were washed
with phosphate-buffered saline (PBS) and centrifuged again.

Protein lysates

were obtained by resuspending PC3 or DU145 cells in 200 pL of ice-cold 1X
CHAPS lysis buffer per 1x106 cells. The CHAPS lysis method was modified from
that presented in Hou et al. and others [176-179]. CHAPS lysis buffer consisted
of

0.5%

3-[(3-Cholamidopropyl)dimethylammonio]-l-propanesulfonic

acid

(CHAPS), 10 mM Tris-HCI, pH 7.5, 1 mM MgCI2, 1 mM ethylene glycol
tetraacetic acid (EGTA), and 10% glycerol. RNase inhibitor (New England
Biolabs, Beverly, MA) (final concentration of 10 units/mL) and B-mercaptoethanol
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(BME) (final concentration of 5 mM) were added just prior to use. Cell lysates
were incubated at 4°C for 30 min and then centrifuged at 12000 x g for 30 min at
4°C.

The supernatant was collected, protein concentration was interpolated

using a Bradford assay and extracts were stored at -86°C.
RTQ-TRAP assay
Telomerase activity was detected by performing real-time quantitative
telomerase repeat amplification protocol (RTQ-TRAP) as derived from a protocol
described by Hou et al. [178].

In detail, each 25 pL RTQ-TRAP reaction

contained: 1X SYBR Green Master mix (50 mM KCI, 20 mM Tris-HCI, pH 8.4, 0.2
mM each dNTP, 3 mM MgCI2, iTaq DNA polymerase at 0.05 units/pL) (Bio-Rad,
Richmond, CA), 10 mM EGTA, 0.2 pg T4 gene protein (New England Biolabs),
0.35 pM TS primer (5-AATCCGTCGAGCAGAGTT-3') (Tm 53.6°C) and 0.35 pM
ACX primer [5'-GCGCGG(CTTACC)3 CTAACC-3T (Tm 66.4°C) [180], and 2.5 pg
of protein extract. Primers were purchased from Integrated DNA Technology
(IDT, Coralville, IA). All samples were analyzed in duplicate or triplicate in a 96well plate on a Bio-Rad CFX96 thermal cycler, and 1X CHAPS buffer was
included as a negative control. Reactions were incubated at 25°C for 20 min to
allow for elongation of the TS primer by cellular telomerase. The PCR protocol
began with a 95°C hot start to activate Taq polymerase, followed by 40 cycles at
95°C for 20 s, 50°C for 30 s, 72°C for 90 s [178], ending with a melt curve
protocol. Telomerase activity was comparatively assessed based on threshold
cycles (CT) [178]. Cr values greater than 35 were considered false positives due
to primer dimers. Inhibition of telomerase activity was determined as follows:

(Cj treatment) - (CT control) = ACT
(1 / 2ACT) X 100 = % ACTIVITY REMAINING
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RTQ-TRAP product analysis by native Polyaerylamide Gel Electrophoresis
(PAGE)
TRAP

products

were

also

analyzed

on

a

non-denaturing

10%

polyacrylamide mini-gel (8.3 x 6.4 x 0.1 cm) (Bio-Rad) in 0.5X Tris-borate-EDTA
(TBE) (50 mM Tris, pH 8.4, 44.5 mM boric acid, 0.5 mM EDTA) buffer. The
protocol was derived from that presented by Dikmen et al. [181]. DNA 100-bp
ladder markers (Bio-Rad) were included for size references. DNA products (~20
pL) were re-suspended 1X Nucleic Acid Sample Loading Buffer (Bio-Rad) and
electrophoresed for 30 min at 200 volts. Gels were then stained with SYBR®
Green I Nucleic Acid Stain (Invitrogen) per manufacturer's suggestions. In most
cases gels were additionally stained with 0.01 mg/mL ethidium bromide for 10
min to obtain the clearest picture. Gels were photographed on a Kodak image
station.
RNA extraction and quantification
Total cellular RNA was isolated using PureZOL™ (Bio-Rad) according to the
manufacturer's protocol.

RNase-free-DNase I digestion (50 units) (Roche

Applied Science, Indianapolis, IN) was also performed. RNA quantification was
determined by UV absorbance on a BioPhotometer Plus (Eppendorf®, Hamburg,
Germany). RNA intactness was assessed by analyzing 28S and 18S subunits of
ribosomal RNA by ethidium bromide 2% agarose gel analysis.
hTERTmRNA levels
Expression of hTERT mRNA was detected using real-time RT-PCR. One
pg of purified cellular RNA from untreated and treated cells was reverse
transcribed into cDNA using iScript (Bio-Rad) at 42°C for 30 min in the presence
of random hexamers and oligo(dT), Moloney murine leukemia virus reverse
transcriptase and RNasin. Analysis of the expression of hTERT mRNA was
performed by real-time PCR amplification using the Bio-Rad CFX96 thermal
cycler. PCR primer sets for hTERT cDNA (GenBank ID: AF015950) and Homo
sapiens 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase cDNA (GenBank
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ID: NM_000859) sequences were optimized using Beacon Designer software
(PREMIER Biosoft International, Palo Alto, CA).

PCR efficiencies for each

primer set were determined in triplicate by a dilution series of the cDNA template.
A master mix contained 1X SsoFast EvaGreen (Bio-Rad), 0.5 |JM of each
forward and reverse primer, and 1.5 |jl of cDNA per reaction. A 140-bp hTERT
fragment was amplified with the primer pair 5'-GAGTGTCTGGAGCAAGTTG-3'
(Tm 52.6°C, located in exon 3) and 5-GGATGAAGCGGAGTCTGG-3' (Tm
53.6°C, located in exon 4) (IDT). A 122-bp reductase amplicon was amplified as
an internal control using the primer pair 5'-TGCAGAGCAATAGGTCTTGGTG-3'
(Tm 58.1°C, spans exons 13 and 14) and 5'-TCGAGCCAGGCTTTCACTTC-3'
(Tm 57.3°C, located in exon 14). The real-time PCR program used was 95°C for
30 s, followed by 35 cycles at 98°C for 30 s, 65°C for 30 s, ending with a melt
curve analysis step where the temperature was reduced to 65°C, then increased
to 95°C in 0.2°C increments every 5 s.

The AACT method was used to

comparatively analyze the data as described in Livak and Schmittgen [182],
Protein extraction and immunoblotting
The protocol described by Peffley et al. [145] was used with minor changes.
Briefly, cells were plated at 3x106 per 100 mm culture dish and allowed to attach
for 24 hr before treating with perillyl alcohol or rapamycin as above. Cells were
lysed in 250

RIPA lysis buffer containing fresh 1X Complete protease inhibitor

cocktail (Roche Applied Science), 1 mM Na3V04 and 1 mM NaF, and protein
concentrations were determined by a Bradford assay.

Protein levels were

assessed by western blotting according to [145] with some modifications. Thirty
to 50 Mg total protein per well were loaded on a 4-15% polyacrylamide TGX minigel (Bio-Rad) and resolved by electrophoresis in 1X Tris-glycine-SDS (0.025 M
Tris, 0.192 M glycine, 0.1% SDS, pH 8.3) for 30 min at 200 volts. Electrophoretic
transfer onto polyvinylidene fluoride (PVDF) membrane was performed in 1X
Tris-glycine buffer. Membranes were blocked in protein-free blok-CH™ buffer
(Millipore, Temecula, CA) for 1 hr at room temperature and then incubated with
gentle rocking in one of the following primary antibodies: mouse monoclonal anti-
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elF4E (1:250, clone P2, Santa Cruz Biotechnology, Inc., Santa Cruz, CA), rabbit
polyclonal anti-hTERT (1:1000; clone Y182, Millipore), rabbit polyclonal antiMKRN1 (Makorin-1) (1.25 MO^L, Abeam, Inc., Cambridge, MA), mouse
monoclonal anti-alpha-tubulin (1:250; clone 10D8, Santa Cruz Biotechnology,
Inc.), or rabbit polyclonal anti-TERT (phospho S824) (1:1000, Abeam, Inc.).
Incubations were conducted overnight at 4°C and followed by extensive
washes in 1X Tris-buffered saline (TBS)-Tween 20 (0.02M Tris, pH 7.4, 0.15 M
NaCI, 0.05% Tween 20). HRP-conjugated secondary antibodies (goat anti-rabbit
or goat anti-mouse [Santa Cruz Biotechnology, Inc.]) were diluted 1:5000 in blokCH™ buffer and incubated for 1 hr at room temperature along with 1 pL
StrepTactin-HRP (Bio-Rad) per 10 ml. solution to visualize Precision Plus protein
standards (Bio-Rad). HeLa nuclear extract (25 pg, Millipore) was used a positive
control for MKRN1 detection. Specificity of the hTERT antibody was confirmed
by comparing band patterns from DU145 cell lysates (with re-activated TERT) to
that of normal human XP30RO fibroblasts (TERT negative) (Coriell Institute,
Camden, NJ).

Anti-actin antibody (1:1000; clone H-300; Santa Cruz) was

included to confirm equal protein amounts in both lanes. Subsequent membrane
washes were as described [145] and then blots were incubated for 5 min in
Immun-Star™ HRP detection system (Bio-Rad) before capturing images on a
Kodak Image Station. Densitometric analysis of protein bands was conducted
using Kodak Molecular Imaging Software version 4.0.4. Band intensities for
proteins of interest were compared relative to the levels of elF4E, which do not
change in response to the above treatments and provide a control for loading
and transfer onto PVDF membranes [145].
Cytoplasmic and nuclear lysates
DU145 cytoplasmic and nuclear lysates were obtained using NE-PER®
Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific, Rockford, IL)
according to manufacturer's instructions.

Briefly, 3x106 DU145 cells were

harvested using trypsin-EDTA, centrifuged at 500 x g for 5 min, rinsed with PBS
and then centrifuged again. The supernatant was removed, and 300 pL of ice-
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cold CER I solution was added. After the appropriate vortexing and incubation
steps, 16.5 pL of CER II solution was added.

Subsequent vortexing and

centrifugation were performed following the manufacturer's protocol, resulting in
a supernatant (cytoplasmic fraction) of DU145 cells and an insoluble pellet. The
insoluble pellet was suspended in 100 pL of NER, vortexed and centrifuged,
which produced a nuclear fraction in the supernatant.
Statistical analysis
All experiments were conducted three to five times with sub-sampling of
each independent quantitative experiment. Data are expressed as a mean +/standard deviation. Data were analyzed using Model I ANOVAs with SPSS
version 19.0. The relationship of interest was perillyl alcohol versus control and
rapamycin versus control; therefore, Dunnett's test was used as a follow-up to
determine statistical significance of the results.
RESULTS
Telomerase activity is decreased by both perillyl alcohol and rapamycin
Telomerase is necessary to maintain telomere lengths in over 90% of
cancers, imparting them with immortality [36]. To examine effects of perillyl
alcohol or rapamycin on prostate tumor cell telomerase activity, we performed
RTQ-TRAP on protein extracts obtained from perillyl alcohol- or rapamycintreated DU145 and PC3 cells. The drug treatment conditions used-400 pM
perillyl alcohol for 16 hr or 10 nM rapamycin for 4 hr-were those shown
previously to suppress 4E-BP1 phosphorylation in human prostate cancer cells
and to inhibit cap-dependent translation via the mTOR pathway [144, 145].
Concentrations used also emulate plasma concentrations of the respective
agents achieved in cancer patients [143, 159], For reference, EtOH- or DMSOtreated control cell protein samples were also analyzed. RTQ-TRAP assay, used
to assess telomerase activity, is preferred over previous TRAP methods due to
its increased sensitivity and quantitative nature based on threshold cycle (CT)
values [178]. A one CT difference between two samples represents a twofold
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Fig. 7. Perillyl alcohol (POH) and rapamycin (Rapa) inhibit telomerase in
DU145 and PC3 cells, (a) Relative levels of telomerase activity in prostate
cancer cells with and without perillyl alcohol or rapamycin determined by RTQTRAP. Cells were treated with one of the following: 400 pM POH for 16 hr, 10
nM Rapa for 4 hr or 0.1% ethanol (EtOH) for 16 hr before lysis in CHAPS
buffer. Open symbols: DU145 cells; solid symbols: PC3. *,0; EtOH. •,•: Rapa.

A, A: POH. Representative results from DU145 and PC3 cell lines assessed by
RTQ-TRAP. An increase in Cj value indicates a decrease in telomerase
activity, (b) RTQ-TRAP assays were run in triplicate and the resultant CT
values for each treatment condition and cell line were averaged. Remaining
telomerase activity was determined as described in Methods relative to EtOHtreated cells, which were set at 100%. Error bars shown represent the mean
+/- standard deviation (SD) of three independent experiments; * represents
significant differences as determined by ANOVA.
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difference in starting material or in this case, a 50% reduction in telomerase
activity; a CR value change of 3.3 represents a 10-fold difference or 90%
reduction in activity. Fig. 7 (a) shows representative results from RTQ-TRAP
experiments that were conducted on standardized protein concentrations at least
three times. In the absence of reagents (EtOH only), DU145 cells (open circles)
were found to have much greater telomerase activity than did PC3 cells (solid
circles), i.e., the average CT value was lower for untreated DU145 for equivalent
protein amounts than that found for untreated PC3 (24.7 and 27.4, respectively in
the experiment depicted)-indicative of greater initial activity. Results from three
separate experiments demonstrated that PC3 cells had ~17% of the telomerase
activity found in DU145 cells. Disparate levels of telomerase activity have been
noted previously for these two lines [183]. A large increase in Cj values (due to
loss of telomerase activity) was identified in perillyl alcohol (open triangles)- and

'4r
8

Fig. 8. Verification of telomerase activity in DU145 and PC3 cell extracts by
PAGE. RTQ-TRAP generated amplicons were electrophoresed on a 10% nondenaturing polyacrylamide mini-gel that was subsequently stained in SYBR
Green and ethidium bromide. Lane 1: 100-bp markers included as a size
reference. Lane 2: Rapamycin-treated PC3. Lane 3: Perillyl alcohol-treated PC3.
Lane 4: PC3 EtOH-treated control sample. Lane 5: No template control sample.
Lane 6: DU145 EtOH-treated control sample. Lane 7: Perillyl alcohol-treated
DU145 sample. Lane 8: Rapamycin-treated DU145 cells.
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rapamycin (open squares)-treated DU145 samples relative to controls (F=
1214.996; df= 2; p<0.0005).

Correspondingly, PC3 samples also showed

attenuated telomerase upon perillyl alcohol (solid triangles) and rapamycin (solid
squares) treatment compared to controls (F=40.275; df=2; p<0.0005).

A

Dunnett's test revealed the significant differences in both cell lines between
perillyl alcohol and control treated sample (DU145 and PC3 p<0.0005), and
between rapamycin and control treated samples (DU145 and PC3 p<0.0005).
Resultant CT values for each treatment condition and cell line were averaged and
remaining telomerase activity determined as described in Methods relative to
EtOH-treated cells, which were set at 100% (Fig. 7, (b)). Perillyl alcohol and
rapamycin inhibited telomerase activity in both cell lines. Treatment

of PC3

cells with perillyl alcohol resulted in ~80% loss of telomerase activity; a 70%
reduction was observed with rapamycin. Correspondingly in DU145 cells, both
perillyl alcohol and rapamycin dramatically attenuated telomerase activity (~93%
and 98%, respectively).
Telomerase activity results were confirmed by analyzing amplicons
generated by RTQ-TRAP on non-denaturing 10% polyacrylamide gels as
modified from Dikmen et al. [181] followed by SYBR Green/ethidium bromide
staining (Fig. 8). The product from the no template control reaction was run on
the gel to account for artifacts due to primer-dimer formation (Fig. 8, lane 5).
RTQ-TRAP-generated amplicons produced a characteristic laddering pattern
indicative of telomerase activity as seen in control lanes for PC3 and DU145
cellular extracts (Fig. 8, Lanes 4 and 6 respectively). Greater telomerase activity
(i.e. number of bands) and band intensities were again apparent in the control
DU145 lane relative to PC3. In perillyl alcohol-treated samples for PC3 and
DU145 cells, there was a marked decrease in the intensity of the ladder (lanes 3
and 7, respectively), and an even further reduction in the intensity after
rapamycin treatment (lanes 2 and 8 respectively), indicating decreased
telomerase activity. Interestingly, we were able to detect the ladder using a minigel. This enables electrophoretic gel analysis in 30 min, versus the standard gel
run of 2-4 hrs.

The waning intensity of the ladders confirmed that low
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Tablet.
Time course of perlltyl alcohol or rapamycln treatment effects on
telomerase activity in DU145 cells.1
Condition

1 hr

2 hr

4hr

Bhr

16hr

POH

82.8+/-19.9

86.5 +/-16.4

92.5 +/-12.8

Rapamycin 88.2 *f- 4.5 922 +/- 5.4

98.3 *b 1.8

T T . I T i r « II II n r .

'Percent reduction in telomerase activity relative to control untreated eels. Each
value represents the mean of three independent replicates +/- standard deviation.
POH » Perillyi Alcohol. Statistical significance of perilyi alcohol treatment vs.
control or rapamytin treatment versus control was assessed using ANOVA with a
Dunnetfs posthoc test.

concentrations and short exposure times of perillyi alcohol or rapamycin were
sufficient to decrease telomerase activity in DU145 and PC3 cells.
The remarkable loss of telomerase activity after relatively brief incubations
with either perillyi alcohol or rapamycin led to examination of even shorter
treatment times to gain insights into their respective mechanisms of modulating
telomerase. In addition, because DU145 cells had significantly greater amounts
of telomerase activity compared to PC3, all additional studies focused on DU145.
Cells were treated with rapamycin for 1 or 2 hr, or perillyi alcohol for 4 or 8 hr,
after which they were lysed and assayed with RTQ-TRAP. Rapamycin markedly
arrested telomerase activity by -88% +/- 4.5% (SD) within 1 hr (Table 1).
Although much smaller and more simple structurally than rapamycin, perillyi
alcohol likewise exerted substantial inhibitory effects at 4 hr and reduced
telomerase by -83% +/-19.9% (SD); at 8 hr incubation, telomerase activity was
attenuated by -87% +/- 16.4% (SD). The rapid inhibition of telomerase activity
by perillyi alcohol and rapamycin provides insights for their mode of action.
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Fig. 9. Quantitative real-time RT-PCR analysis of hTERT mRNA levels in DU145
cells treated with perillyl alcohol or rapamycin. hTERT mRNA expression was
determined based on CT values. Levels were normalized to the expression of
HMG CoA reductase and expressed as fold change. No significant difference is
detected when comparing treatment groups to control. Results are shown as a
mean +/- SD of at least three experiments.

Neither perillyl alcohol nor rapamycin alters hTERT mRNA levels
Telomerase activity is regulated at both transcriptional and translational
levels, although transciptional processes have been identified as the critcal
governing factor [44], mRNA levels of hTERT, the rate limiting component of
telomerase, correlate to telomerase activity [184].

Rapamycin-at high

concentrations and/or for long periods (48 to 72 hr)-has been reported to
decrease hTERT mRNA levels [146, 147]. Likewise, 24 hr cellular treatment with
the isoflavone genistein reduced hTERT mRNA expression [185], Using real
time RT-PCR, we examine if telomerase activity was altered by perillyl alcohol
due to changes in hTERT mRNA levels, and to verify the reported effects of
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Fig. 10. Western blot analysis to detect hTERT protein levels in DU145 cells
following perillyl alcohol or rapamycin treatments, (a) Lanes 1-3 were loaded
with 50 pg of DU145 total protein. Lane 1: control DMSO-treated sample. Lane
2: 400 pM perillyl alcohol for 16 hr. Lane 3: 10 nM rapamycin for 4 hr. Lane 4:
Precision Plus Protein™ WesternC™ Standards. Membrane in the top panel
was probed with an anti-hTERT antibody, (b) Depiction of the western blot
produced by probing with anti-elF4E antibody as a loading control. B. Histogram
representation of four independent experiments +/-1 standard deviation.
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rapamycin (Fig. 9). An internal control gene was included-HMG-CoA reductasewhose mRNA level does not change in response to perillyl alcohol and
rapamycin

[145],

Real-time

RT-PCR

analysis

showed

that

at

the

pharmacologically relevant levels used during this study [143, 159], neither
perillyl alcohol (0.4 mM, 16 hr) nor rapamycin (10 nM, 4 hr) produced a
significant decrease in their respective average

Ct

values in DU145 cells as

compared to untreated controls when normalized to HMG-CoA reductase levels
as described in Livak and Schmittegn (F= 0.219; df=2; p= 0.808) [182], Thus,
neither perillyl alcohol nor rapamycin-under the conditions used here-appear to
regulate telomerase activity at the transcriptional level.
hTERTprotein levels diminish after perillyl alcohol or rapamycin incubation
Additional levels of telomerase regulation due to post-translational
processes such as hTERT protein phosphorylation, cellular localization and/or
degradation are known [43]. It was hypothesized that a direct translational effect
due to suppressed 4E-BP1 phosphorylation and therefore decreased hTERT
protein synthesis by either compound was likely. Further, due to the rapid rate of
reduction observed in the above studies, telomerase activity inhibition may be
additionally modulated at a post-translational level. Western blot analysis was
then conducted to assess possible hTERT protein level changes in response to
treatments with perillyl alcohol or rapamycin.

After transfer onto PVDF,

membranes were incubated with either rabbit anti-hTERT (detects ~122 kDa
protein) or mouse anti-elF4E (~28 kDa protein) as a control for loading (Fig. 10
(a)). Densitometric analysis was performed on the western blot bands; results
from four independent experiments are shown (Fig. 10 (b)). Bands resulting from
the DU145 protein lysates treated with either perillyl alcohol or rapamycin were
compared to the band intensity resulting from the control-treated sample (lane 1,
Fig. 10 (a)). Perillyl alcohol treatment reduced hTERT protein levels by ~30%
(lane 2), whereas rapamycin treatment (lane 3) caused a -65% reduction in
hTERT protein levels. Four independent experiments produced similar results
with ~40% loss of hTERT protein after perillyl alcohol treatment, and ~76% loss
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-53 kD
MKRN1
-28 kD
elF4E

Fig. 11. Western blot analysis to detect MKRN1 expression after perillyl
alcohol or rapamycin treatment. Lanes 2-4 were loaded with 50 M9 of total
protein from DU145 cells.

Lane 1:

Precision Plus Protein™ WesternC™

Standards. Lane 2: Rapamycin-treated sample. Lane 3: Perillyl alcohol treated sample. Lane 4: Control (DMSO)-untreated sample. Lane 5: HeLa
nuclear extract (25 pg) was run as a positive control. Membranes were probed
with anti-MKRN1 (top); antibody against elF4E was used as a loading control
(bottom).

of protein after rapamycin (F=63.893; df= 2; p<0.0005). A Dunnett's test further
revelead that loss of hTERT protein caused by either perillyl alcohol or rapamycin
were both highly significant (p<0.0005). Thus, perillyl alcohol and rapamycin
lowered hTERT protein levels with short exposure times and at biologically
relevant concentrations. This significant attenuation of hTERT protein by either
agent supports an effect on protein translation mediated by the mTOR pathway.

Degradation of hTERT by Makorin-1 does not appear to contribute to loss of
hTERT protein
Degradation of hTERT is controlled by Makorin-1 (MKRNI)-an E3 ligase
that mediates ubiquitination of hTERT for proteasome processing [74, 75].
Cancer cells typically contain low MKRN1 levels [75], However, MKRN1 mRNA
and protein levels rise dramatically in G1 arrest to signal the proteolytic
breakdown of hTERT [75]. Perillyl alcohol and rapamycin treatment cause G1
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Fig. 12. Western blot analysis to detect cellular localization changes after perillyl
alcohol or rapamycin treatment, (a) Lanes 2, 4, and 6 were loaded with 40 pg of
cytoplasmic protein from DU145 cells. Lanes 3, 5, and 7 were loaded with 40 pg
of nuclear protein from DU145 cells.
WesternC™ Standards.

Lane 1: Precision Plus Protein™

Lanes 2 and 3: Control (EtOH)-untreated samples.

Lanes 4 and 5: Perillyl alcohol-treated samples. Lanes 6 and 7: Rapamycintreated samples.

Membranes were probed with anti-TERT antibody (Top);

antibody against alpha-tubulin was used as a loading control (Bottom), (b)
Histogram representation of four independent experiments +/- 1 standard
deviation.
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arrest in DU145 cells and a concomitant increase in p21ap levels [186]. Therefore
western blotting was used to examine whether MKRN1 levels increased after
either treatment, which would cause the ubiquitination and degradation of hTERT
(Fig. 11). MKRN1 protein was not detected in control-treated DU145 cells (Fig.
11, lane 4).

Furthermore, no increase was noted with perillyl alcohol or

rapamycin treatment (lanes 3 and 2, respectively).

MKRN1 protein was

observed in the control lane (lane 5) with 25 |jg nuclear extract from HeLa cells,
which are reported to have low but measurable MKRN1 levels [75].

Longer

exposures (20 min vs. 2 to 10 min) likewise did not reveal MKRN1 protein bands
in DU145 cellular extracts.

Cellular localization of hTERT and phosphorylation status
Telomerase activity is also dependent on phosphorylation and nuclear
localization of the hTERT protein [63]. Telomerase activity is thought to be
modulated through phosphorylation of the hTERT subunit at Ser824 (and other
sites such as Ser1125 and Ser227) by Akt protein kinase [61] and by various
protein kinase

C isoenzymes

[67,

187,

188].

Conversely, decreased

phosphorylation of Ser 824 with concomitant phosphorylation of Tyr707 is
associated with hTERT export out of the nucleus into the cytoplasm [73, 189],
To compare the effects of perillyl alcohol and rapamycin on hTERT cellular
distribution, nuclear and cytoplasmic fractions were separated and hTERT levels
in both fractions analyzed by western blotting (Fig. 12 (a)). hTERT protein was
found in both the nucleus and cytoplasm of untreated DU145 cells, with greater
protein in the cytoplasm. In response to isoprenoid or rapamycin treatment, no
appreciable redistribution of hTERT protein from the nucleus into the cytoplasm
was detected. Instead, protein levels in both fractions decreased relative to their
counterpart control amounts. With the caveat that western blots are only semi
quantitative, densitometric analyses of band intensities relative to alpha-tubulin
(loading control) from four experiments revealed that in response to perillyl
alcohol, nuclear hTERT protein levels decreased by ~52 %, and that in the
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Fig. 13. Western blot analysis to detect phosphorylation changes after perillyl
alcohol or rapamycin treatment, (a) Lanes 2-4 and 7-9 were loaded with 50 pg
of total protein from DU145 cells. Lanes 1 and 6: Precision Plus Protein™
WesternC™ Standards. Lanes 2 and 7: Control (EtOH)-untreated samples.
Lanes 3 and 8: perillyl alcohol-treated samples. Lanes 4 and 9: Rapamycintreated samples. Lane 5 was loaded with running buffer. Membranes were
probed with anti-phospho (Ser824)-TERT (Top left); anti-TERT (Top right);
antibody against elF4E was used as a loading control (bottom), (b) Histogram
analysis of five independent experiments +/-1 standard deviation.
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cytoplasmic fraction decreased by -40 % (F=0.493; df=1; p=0.505) (Fig. 12 (b)).
Rapamycin treatment mimicked this trend. hTERT protein in nuclear fractions
declined by -77 % compared to that in the cytoplasm, which was reduced by -61
% (F=0.151; df=1; p=0.709).

In both situations, the respective reductions in

nuclear and cytoplasmic hTERT protein levels were not significantly different
than the total loss of protein observed after either treatment.

The

phosphorylation status of hTERT Ser824 in response to either treatment
condition was also assessed (Fig. 13 (a) and (b)).

The dephosphorylation

pattern followed the reduction in hTERT protein levels.

Results from four

experiments showed that perillyl alcohol treatment caused a -41 % decrease in
hTERT protein and a -56 % loss of hTERT (Ser824) phosphorylation (F=1.048;
df=1; p=0,336) (Fig. 13 (b)). Rapamycin caused a -60 % reduction in hTERT
protein and -46 % loss in Ser824 phosphorylation (F=2.315; df=1; p=0.167)(Fig.
13 (b)). There is no significant difference in the the decrease in hTERT Ser824
phosphorylation with either perillyl alcohol or rapamycin treatment versus the loss
of hTERT protein observed. Hence the loss of telomerase activity is not due to a
change in Ser824 phosphorylation or due to export of the protein from the
nucleus.

DISCUSSION
The rate-limiting component of the telomerase holoenzyme, hTERT, is
regulated by both transcriptional and post-transcriptional factors, such as mRNA
levels, cellular localization of hTERT protein, hTERT phosphorylation and protein
degradation [43],

Somatic cells and normal cells in culture do not have

detectable levels of hTERT mRNA, although the RNA component-/)TERC-is
present [45]. Eventually normal cultured cells enter into crisis; all but a few will
succumb to apoptotic death [46],

The few cells that survive crisis become

immortalized as detected by a surge in hTERT mRNA levels [45]. Comparable
transcriptional derepression of hTERT is observed in patients' tumor cells relative
to adjacent normal tissues [45]. The promoter region of the hTERT gene has
multiple binding sites for a vast array of transcription factors, providing clues to
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the extent of regulatory complexity [47]. Specifically, two Myc/Max binding sites
(E-boxes) have been identified in the hTERT promoter, and c-myc directly
activates hTERT transcription [48-50]. It is well known that c-myc activation is an
early event in nearly all cancers as is telomerase activation. However, after
hTERT transcription has been de-repressed, molecular failsafes remain to
squelch the pro-cancer activities of a cancer cell apprentice. Posttranscriptional
control of hTERT becomes the cell's last resort to forestall telomerase activation
and therefore immortalization.
Results of this study demonstrate that both perillyl alcohol and rapamycin
attenuate telomerase activity without altering hTERT mRNA levels. The ability of
perillyl alcohol-a structurally simple plant monoterpene-to inhibit telomerase
activity has not been previously reported. These findings indicate that effects
on hTERT core promoter by either perillyl alcohol or rapamycin are not involved
in repression of telomerase activity. In addition, hTERT mRNA stability is an
unlikely target because mRNA levels did not change within the time-frame
studied.

Thus perillyl alcohol and rapamycin appear to act as sentinels to

counter increased hTERT mRNA levels. These results with perillyl alcohol
contrast to those reported for genistein-a soybean-based natural product-and
other isoflavones or plant products that appear to regulate telomerase
transcriptionally [65, 161, 185, 190]. Likewise, epicatechins found in green tea
have been reported to down-regulate hTERT mRNA levels in carcinoma cells
[191]. Zhao (2008) and Zhou (2003) also found decreased hTERT mRNA levels
with high concentrations (100 - 1000 nM) and long incubation times (48 to 72 hr)
of rapamycin [146, 147],

Others have established that genistein depletes

telomerase via an epigenetic mechanism-through site specific hypo-methylation
at an E2F-1 binding site in the hTERT promoter [60, 188].
In the absence of hTERT mRNA inhibition, we proposed that perillyl alcoholand rapamycin-mediated loss of telomerase activity were likely due to
translational (hTERT protein synthesis) or a combination of translational and
post-translational mechanisms such as phosphorylation, nuclear translocation or
degradation of the hTERT protein. Our experiments clearly demonstrated that
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both agents instigated a significant loss of hTERT protein. The half life of hTERT
has been reported at ~ 6 to 12 hr depending on the cell type studied [178, 192].
Protein loss was observed at 4 hr treatments, therefore it could be due in part to
inhibition of translation initiation and protein turnover attributed to effects of either
compound on S6 kinase and/or 4E-BP1.

Within this work, protein turnover

cannot be ruled out or distinguished from degradation. Importantly the findings
that rapamycin, the classical mTOR inhibitor, or perillyl alcohol, an isoprenoid
with known anti-mTOR effects, both decrease hTERT protein provides
compelling evidence that perillyl alcohol or rapamycin-mediated control of
telomerase is due to translational mechanisms mediated by the mTOR pathway.
Likewise our findings are noteworthy in that biologically relevant
concentrations and brief exposure times for perillyl alcohol or rapamycin were
used: 0.4 mM for 16 hr, and 10 nM for 4 hr, respectively. Under these conditions,
suppressed phosphorylation of a downstream target of mTOR (4E-BP1),
disruption of the m7GpppX cap binding complex elF2F and/or inhibition of capdependent translation have been observed [144, 145, 193]. Shorter incubation
times with either agent likewise resulted in attenuated telomerase activity. Thus
the cellular effects are very rapid. In contrast, virtually all of the studies cited
above-in which hTERT mRNA effects were observed-were performed for 24, 48,
or 72 hrs. We believe the transcriptional effects on hTERT may be due to the
secondary effects of shutting down cap-dependent translation through the mTOR
pathway for a prolonged period of time.

It should be emphasized that the

maximum tolerated dose of oral rapamycin administered to adult cancer patients
on a daily basis has been reported at ~6 mg/d, which results in a maximal
plasma concentration of ~22 nM [143].

Correspondingly, the perillyl alcohol

concentration used in this study emulates plasma concentrations of perillic acidthe main metabolite of perillyl alcohol detected in patients [159, 194],

The

suprapharmacological rapamycin concentrations used in the above two in vitro
studies and/or prolonged incubations are unwarranted, and effects observed
likely reflect accumulating damage to cellular components, secondary metabolic
effects and possibly autophagy [195]. In addition, drug studies conducted with
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unrealistic concentrations may disguise the true cellular pathways modified or
provide artifactual results [196, 197],
Moreover, western blot results revealed that MKRN1- the E3 ligase known
to target hTERT for degradation- was not up-regulated in perillyl alcohol- and
rapamycin-treated cells, a result somewhat surprising based on several earlier
reports linking hTERT degradation to MKRN1 [74, 75, 192]. However, the
findings should have been anticipated to some extent. Although previous studies
found that MKRN1 mRNA and protein levels rose dramatically (~6 fold) after
either cell cycle arrest was induced [75] or a chaperone inhibitor geldanamycin
was used [74], the enhanced MKRN1 protein levels occurred over a period of 6
to 12 hrs [75]. Effects observed with both perillyl alcohol and rapamycin were
much faster in the present experiments, in which diminished telomerase activity
was measured 1 or 2 hr post-rapamycin incubation or after a 4 hr perillyl alcohol
treatment.

Due to the rapid decrease in protein observed in the current

experiments, ubiquitination and proteasome breakdown of hTERT may indeed
still have a role, but it is unlikely to involve MKRN1. Lee and Chung (2010) and
Kim et al. (2005) have proposed that hTERT degradation may be mediated
additionally by Hsp90/Hsp70-associated U-box ubiquitin ligase CHIP or other
unidentified E3 ligases [74, 192],
The rapidity at which a decline in telomerase activity was detected with
rapamycin (1 hr) or with perillyl alcohol (4 hr) incubation led us to explore
supplementary telomerase activity regulation at a post-translational level.
Intracellular reshuffling of hTERT contributes to post-translational regulation of
telomerase activity [63]. hTERT redistribution between the nucleus and
cytoplasm with nuclear localization is thought to be essential for telomerase
activity [63, 66]. However, our findings show that neither perillyl alcohol nor
rapamycin causes cellular redistribution of hTERT. Interestingly, the average of
the cytoplasmic and nuclear loss of hTERT is approximately equivalent to the
total loss of hTERT seen in the previous studies (data not shown).
As a corollary to the cellular localization studies, hTERT phosphorylation
status was examined to confirm the absence of hTERT redistribution.
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Phosphorylation events have been linked to hTERT exit from or entrance into the
nucleus. In accordance with the above results, we did not detect a change in
phosphorylation of hTERT (Ser824), which has been shown to be targeted by Akt
[61]. Furthermore, our findings are consistent with previous observations that
neither perillyl alcohol nor rapamycin suppressed Akt (Ser473) phosphorylation in
prostate cancer cell lines [145]. Conversely, agents that do affect Akt kinase
activity, such as a PI3-kinase inhibitor wortmannin, inhibit telomerase activity and
downregulate hTERT protein phosphorylation [61]. Jagedeesh et al. (2006) also
reported that 50 |jM genistein treatment of DU145 cells for three days decreased
phosphorylation of Akt (Ser473) concomitant with a reduction of hTERT protein
phosphorylation (non-specific serines) [65]. Likewise, hTERT translocation into
the nucleus was prevented. Clearly a change in phosphorylation status did not
contribute to the rapid loss of telomerase activity that we observed with our short,
biologically relevant treatment parameters.
Rapamycin has been touted as a new potent cancer chemopreventive agent
[149, 150], but concerns about toxic side effects (immunosuppression), safety
(feedback activation of Akt and enhanced tumorigenesis) and pharmacokinetic
issues temper enthusiasm for this approach [151, 152], The potential efficacy of
naturally occurring dietary factors with relatively low acute toxicity [153] contrasts
to that of rapamycin; consequently, isoprenoids represent a more cogent and
effective method for cancer prevention.

Perillyl alcohol exhibits clear and

definitive effects on a distinct signaling pathway-mTOR-that has a strong, critical
clinical role as well as a role in cell proliferation. Dietary compounds such as
isoprenoids likely contribute to chemoprevention by inhibiting a slight growth
advantage (or hyperproliferation) in an early stage or pre-malignant cell, and
there is evidence that metastasis and angiogenesis are also targeted [198]. In
this study we have uncovered an additional target-telomerase activity-that may
be paramount in the chemopreventive capacity of perillyl alcohol. All cancers are
excellent candidates for chemopreventive measures and approaches, but
prostate cancer is particularly appropriate due to its relatively long latency, late
age of onset, slow growth, and high incidence [171, 199, 200]. Our findings also
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emphasize that isoprenoids may be important clinically not as single agents but
rather as chemotherapeutic adjuvants or sensitizing agents to diminish
telomerase activity in tumor cells.
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CHAPTER III

DISRUPTION OF A HTERT-MTOR-RAPTOR PROTEIN COMPLEX BY THE
PHYTOCHEMICAL PERILLYL ALCOHOL AND RAPAMYCIN

INTRODUCTION
Gene regulation is a complex process mediated by numerous cellular
pathways. At the forefront of current gene regulatory mechanism research are
post-translational modifications that alter the ability of a protein to perform its
functions. Traditional mechanisms of post-translational regulation include protein
folding, phosphorylation changes, and cellular localization. An equally important
post-translational process is the assembly of proteins into complexes that allow a
cell to carry out diverse functions that the individual proteins found in the complex
could not perform on their own. Determining which proteins are in the complex of
interest discloses clues about regulation of the cellular process imparted by the
complex. This molecular puzzle of protein interactions in a complex ultimately
reveals regulation.
Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that is
the central player in numerous protein complexes. One of its primary functions,
regulation of cap-dependent translation, is mediated through phosphorylation of
4E-BP1. mTOR's association with various protein complexes imparts unique
regulatory functions, a process that emphasizes the importance of protein-protein
interactions and associated complex formation in expanding the regulatory role of
individual proteins. For example, through multiple protein interactions mTOR not
only regulates protein translation, but also cell growth and cell size, as well as
autophagy and ribosome biogenesis.
mTOR associates with RAPTOR in a complex termed mTORCI that
governs cap-dependent translation [109]. Further, the downstream targets of
mTORC1-S6K and 4E-binding protein 1 (4E-BP1)-have been shown to
physically associate with RAPTOR in a larger complex [201, 202]. mTORCI
phosphorylates S6K and 4E-BP1, and complex formation apparently facilitates
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the efficiency at which down-stream signaling may occur. Hsp90 likewise forms
a physical complex with RAPTOR and is required for certain mTORCI functions
in the complex [203, 204]. Furthermore, inhibition of Hsp90 decreases RAPTOR
expression, suggesting that Hsp90 may stabilize this complex [204].
Hsp90 is also an integral part of the telomerase complex. Hsp90 and a cochaperone p23 are required for efficient telomerase activity [205]. Telomerase
provides immortality to most cancer cells by extending telomeric DNA sequences
with a hexameric repeat, thus allowing cancer cells to escape senescence.
Human telomerase enzyme is minimally composed of hTERT-the catalytic
subunit and reverse transcriptase-and hTERC, the RNA component [2, 16, 40,
60]. Other proteins such as dyskerin have also been found to be supporting
members in the telomerase complex. Kawauchi et al. further described that upon
IL-2 stimulation of natural killer (NK) cells, telomerase activity was de-repressed,
and hTERT protein formed a physical and functional complex with mTOR, S6K,
Hsp90 and Akt [70], The inclusion of mTOR and S6K in the hTERT complex is
persuasive evidence to support mTOR-mediated control of telomerase activity.
Using a plant-derived isoprenoid-perillyl alcohol-and the classical mTOR
inhibitor-rapamycin-we recently demonstrated that both agents rapidly and
effectively attenuate telomerase activity and hTERT protein levels in human
prostate cancer cells.

These decreases in telomerase activity and hTERT

protein levels occur in the absence of any effect on hTERT mRNA (Chapter 2).
Both compounds were previously observed in our laboratory to suppress 4E-BP1
phosphorylation and cap-dependent translation in cancer cells [144, 145],

In

addition, the known mechanism of action for rapamycin involves dissociation of
the endogenous mTOR-RAPTOR complex with a concomitant suppression of
mTOR kinase activity [139, 206]. The ability of perillyl alcohol to likewise disrupt
the mTOR-RAPTOR complex as a mechanism to down-regulate protein
synthesis has not been explored.
Based upon the known important protein interactions described above, we
hypothesized that an hTERT-mTOR-RAPTOR complex exists in prostate cancer
cells. As demonstrated in this study, perillyl alcohol and rapamycin-mediated
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dissociation of this complex has a unique role in post-translational inhibition of
telomerase activity.
MATERIALS AND METHODS
Cell lines and cell culture
Human prostate cancer cell line DU145 (American Type Culture Collection,
Manassas, VA) was maintained at 37°C in a humidified incubator with 5% CO2 in
RPMI-1640 medium supplemented with 10% fetal bovine serum, 1X glutamine
and 1X penicillin/streptomycin. Growth medium was changed every other day.
Drug treatments
Perillyl alcohol (Sigma-Aldrich, St. Louis, MO) was prepared in 100%
ethanol; rapamycin (Cell Signaling Technology, Danvers, MA) was dissolved in
100% DMSO [145]. DU145 cells were plated at a concentration of 3x106 cells
per 100 mm plate in 8 mL medium and allowed to attach overnight. Cells were
then treated with one of the following: 400 pM perillyl alcohol for 16 hr, 10 nM
rapamycin for 4 hr, or 0.1% ethanol for 16 hr as described by Peffley et al. [145].
Concentrations used emulate plasma concentrations of the respective agents
reported in clinical studies on cancer patients [143, 159],
Protein extraction and immunoprecipitation
Cells were extracted using the Pierce® Classic IP kit according to the
manufacturer's instructions. The IP lysis/wash buffer was supplemented with 1X
Complete protease inhibitor cocktail (Roche Applied Science), 1 mM Na3V04 and
1 mM NaF. Protein concentration was interpolated using a Bradford assay and
extracts were either analyzed immediately or stored at -86°C.
The complex of interest was captured using the Pierce® Classic IP kit
according to the manufacturer's instructions. Briefly, 5 pg of rabbit polyclonal
anti-RAPTOR antibody (Millipore) or 5 pg of anti-IgG (clone Sc-2027; Santa
Cruz) was incubated overnight with 1 mg of protein extract in the IP lysis/wash

buffer with end-over-end mixing.

Protein A-Sepharose from Staphylococcus

aureus (Sigma-Aldrich®) was resuspended (1:1) in PBS. Thirty |JL of protein ASepharose slurry was applied to the Pierce spin column. Washes were carried
out according to the manufacturer's protocol. The protein-antibody solution was
applied to the spin column containing protein A-Sepharose and incubated for 1 hr
at 4°C with end-over-end mixing.

Subsequent washes were carried out

according to the manufacturer's protocol. The complex was eluted from the
column/beads following the sample-buffer elution protocol provided in a 2X SDS
loading dye. Eluted protein was subsequently used in the western blot protocol.
SDS-PAGE and western blot
One half the volume of captured protein was loaded per well on a 4-15%
polyacrylamide TGX mini-gel (Bio-Rad) and resolved by electrophoresis in 1X
Tris-glycine-SDS (0.025 M Tris, 0.192 M glycine, 0.1% SDS, pH 8.3) for 30 min
at 200 volts.

Odyssey® two-color protein molecular weight markers were

included to determine protein sizes; all subsequent steps were performed with
minimal light exposure.

Electrophoretic transfer onto polyvinylidene fluoride

(PVDF) membrane was performed in 1X Tris-glycine buffer. Membranes were
blocked in protein-free blok-CH™ buffer (Millipore) for 1 hr at room temperature
and then incubated with gentle rocking in one of the following primary antibodies:
rabbit polyclonal anti-RAPTOR (1:1,000; Millipore) (capture/loading control),
rabbit polyclonal anti-hTERT (1:1000; clone Y182, Millipore), rabbit polyclonal
anti-mTOR (1:1,000; Cell Signaling Technology®), rabbit polyclonal anti-Hsp90
(1:1,000; clone C45G5, Cell Signaling Technology®), or rabbit polyclonal antip70 S6 kinase (1:1000; Cell Signaling Technology®).
Incubations were conducted overnight at 4°C and followed by extensive
washes in 1X Tris-buffered saline (TBS)-Tween 20 (0.02M Tris, pH 7.4, 0.15 M
NaCI, 0.05% Tween 20). IR-conjugated secondary antibodies (goat anti-rabbit
[IRDye 680LT] or goat anti-mouse [IRDye 800 C\N]) were diluted 1:5000 in blokCH™ buffer and incubated for 1 hr at room temperature. Subsequent membrane
washes were as described [145], and then blots were washed for 5 min in PBS

54
before capturing images on an Odyssey Infrared Imaging System (Licor®). Band
intensities were assessed subjectively.
SDS-polyacrylamide gel silver staining
Immunocaptured

proteins

separated

by

SDS-polyacrylamide

gel

electrophoresis were detected by silver staining using the Pierce® Silver Stain Kit
according to the manufacturer's suggestions. Experiment was repeated twice
with similar results.
RESULTS
Perillyl alcohol or rapamycin treatment causes changes in the protein complex
associated with RAPTOR
We previously demonstrated in DU145 prostate cancer cells that perillyl
alcohol and rapamycin dramatically and rapidly attenuate telomerase activity
without altering hTERT mRNA levels (Chapter 2).

With these two agents,

suppressed phosphorylation of a downstream target of mTOR (4E-BP1),
disruption of the m7GpppX cap binding complex elF2F and/or inhibition of capdependent translation have been observed in our laboratory [144, 145].
Importantly, hTERT protein levels were diminished by both agents, supporting an
effect on 4E-BP1 and/or S6K phosphorylation and reduced initiation of protein
translation. However, we also noted that the reduction in hTERT protein did not
coincide wholly with loss of telomerase enzymatic activity, suggesting a further
level of regulation. Rapamycin in complex with FKBP12 (FK506- binding protein
of 12 kDa) causes the dissociation of RAPTOR from mTOR, disrupts coupling of
mTOR with its substrates and interferes with its kinase ability [206].

We

therefore reasoned that the rapid modulation of telomerase activity in DU145
cells by perillyl alcohol or rapamycin was attributable in part to destabilization of
an hTERT-mTOR-RAPTOR complex.
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Fig. 14. Perillyl alcohol and rapamycin induce changes in proteins
immunoprecipitated with RAPTOR in DU145 prostate cancer cells. Cells were
treated with 400 |JM perillyl alcohol (POH) for 16 hr, rapamycin (Rapa) at 10
nM for 4 hr, or 0.1% ethanol (EtOH) for 16 hr. Cellular extracts (500 pg) were
incubated with anti-RAPTOR or anti-IgG antibodies and captured on Protein
A-Sepharose.

Proteins were eluted from the column/beads, separated by

SDS-PAGE and detected by silver staining.

Lane 1: Odyssey® two-color

protein molecular weight markers (M). Lanes 2-5: 25 (il of eluted protein from
the column/beads treated as indicated. Lettered arrows point out bands of
interest.

Thus we used co-immunoprecipitation with a RAPTOR antibody and
protein gel silver staining to detect RAPTOR-associated proteins in DU145 cells
and to elucidate potential changes to the captured protein complex caused by
either 400 pM perillyl alcohol for 16 hr, or rapamycin at 10 nM for 4 hr.
Treatment with either perillyl alcohol or rapamycin modified the protein complex
captured with RAPTOR antibody compared to untreated cells; moreover distinct
differences were found between the two agents (Fig. 14).

The pronounced

bands at ~25 kDa and -50 kDa are due to the light and heavy IgG chains,
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Fig. 15. Perillyl alcohol and rapamycin destabilize the hTERT-mTORRAPTOR complex found in DU145 prostate cancer cells. Representative
western blots of RAPTOR-immunoprecipitated proteins are shown.

Cells

were treated and immunoprecipitated as described in Figure 14.

After

capture with anti-RAPTOR antibody and separation on SDS-PAGE, proteins
were transferred to a PVDF membrane, and blocked prior to incubation with
primary antibodies, (a) Blots were subsequently probed with anti-RAPTOR,
anti-Hsp90, anti-S6K, or anti-mTOR antibodies as indicated, (b) Blots were
probed with anti-RAPTOR or anti-hTERT antibodies. IgG: Negative control
anti-IgG captured protein from EtOH-treated DU145 cells. All experiments
were replicated at least five times with similar results.
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respectively.

Perillyl alcohol and rapamycin both suppressed proteins of

approximately 170-180 kDa (A) and ~75 kDa (C) molecular mass (Fig. 14). The
decrease in the 75 kDa (C) protein appeared to be greater with rapamycin than
with perillyl alcohol (Fig. 14). Interestingly, rapamycin caused the loss of a -100
kDa (B) protein, whereas perillyl alcohol increased the level of a protein at the
same position on the gel (Fig. 14). Most noteworthy was the addition of a ~60
kDa (D) protein to the complex by both perillyl alcohol and rapamycin treatments
(Fig. 14).
Perillyl alcohol or rapamycin causes hTERT, S6K, Hsp90, and mTOR to
dissociate from RAPTOR
Cellular functions are often revealed through identification of protein
complexes. Therefore, we assessed by western blotting for the presence or
absence of protein partners described originally by Kawauchi et al. in an
immunoprecipitated complex [70],

In control EtOH-treated cell extracts,

immunoprecipitation with RAPTOR captured mTOR, S6K, Hsp90, and hTERT
(Fig. 15 (a) and (b)) affirming the presence of a similar complex in DU145 cells.
The

above proteins

were

not

detected

immunoprecipitated with normal rabbit IgG.

when

cellular

extracts

were

Although binding of 4E-BP1, a

known RAPTOR-interacting protein, to the complex is of interest, it has a
molecular weight of ~15-20 kDa; therefore its presence is masked by the IgG
light chain. Further, the interaction between RAPTOR and 4E-BP1 has been
previously confirmed [201, 207],
Similarly, Akt, has a molecular weight of 60 kDa, consequently the heavy
chain IgG band conceals the protein band. However, immunoprecipitation with
anti-Akt antibodies revealed the presence of hTERT, Hsp90, and mTOR (data
not shown). The Hsp90 band was the most intense confirming a direct physical
interaction with Akt.

Additionally, the amount of these proteins that

immunoprecipitated with Akt decreased in response to perillyl alcohol or
rapamycin treatment. S6K did not co-immunoprecipitate with Akt, suggesting
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Fig. 16.

Anti-mTOR immunoprecipitation confirms perillyl alcohol or

rapamycin-mediated disruption of the hTERT-mTOR-RAPTOR complex. Cells
were treated as described in Figure 14. Immunoprecipitations were conducted
with either anti-mTOR or anti-IgG antibodies as a control.

Blots were

subsequently probed with anti-mTOR, anti-hTERT, anti-RAPTOR, anti-Hsp90
or anti-S6K antibodies as indicated. IgG: Negative control anti-IgG captured
protein from EtOH-treated DU145 cells. POH, perillyl alcohol. All experiments
were replicated at least five times with similar results.

they are not physically interacting with one another, but rather they are in the
complex through common associations with another protein (data not shown).
Upon treatment with either perillyl alcohol or rapamycin, S6K completely
dissociated from RAPTOR (Fig. 15 (a)). Additionally, a reduction in the amount
of Hsp90 bound to RAPTOR was observed after either treatment. As expected
based on previous literature reports, mTOR also separated from RAPTOR in
cells treated with rapamycin [139]. A decrease in mTOR binding to RAPTOR

mTORCl

Fig. 17. Amended schematic model of the hTERT-mTOR-RAPTOR
complex in DU145 cells. This schematic represents a more accurate
model of the protein-protein interactions involved in the hTERT-mTORRAPTOR

complex based upon

our immunoprecipitation results.

Treatment with either perillyl alcohol or rapamycin impairs the structural
integrity of the complex.

was similarly noted in perillyl alcohol-treated samples, although the reduction
was not as great as that detected with rapamycin (Fig. 15 (a)). Most interesting
for our studies was the loss of hTERT binding to the RAPTOR-captured complex
after treatment with either agent (Fig. 15 (b)). Importantly, perillyl alcohol caused
a larger loss of hTERT protein than rapamycin did. This finding coupled with our
previous reported results on the ability of these agents to attenuate telomerase
activity and protein levels further supports our hypothesis of mTOR-mediated
translational and post-translational regulation of hTERT.

Perillyl alcohol or rapamycin causes hTERT, S6K, Hsp90, and RAPTOR to
dissociate from mTOR
As a corollary experiment, an antibody directed against mTOR was also
used to co-immunoprecipitate the hTERT-mTOR-RAPTOR complex. The ability
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of perillyl alcohol or rapamycin to compromise the structural integrity of the
complex was also examined. Capturing protein binding partners in the complex
with a different antibody could also potentially reveal specific physical
interactions. Western blot analysis demonstrated that the mTOR antibody
immunoprecipitated RAPTOR, Hsp90, S6K and hTERT (Fig. 16).

Similarly,

interactions among all four proteins with mTOR were disrupted by perillyl alcohol
and rapamycin. Rapamycin and perillyl alcohol treatment decreased binding of
RAPTOR and Hsp90 to mTOR, with rapamycin being more effective than perillyl
alcohol. Although we detected a decrease in the hTERT and S6K bands upon
treatment with either agent, the basal protein levels that immunopreciptated with
mTOR were low. Our results are consistent with the postulate that the interaction
between these two proteins with mTOR is via RAPTOR.
DISCUSSION
Protein complexes are the capstone of numerous cellular processes.
Protein-protein interactions within these complexes add unique functions that
individual proteins lack. Although it was surprising to find hTERT associated with
a protein complex that included mTOR, it does provide a critical link between
telomerase activity and a major signal transduction pathway that regulates cell
cycle progression [70],

Here we have found that a complex similar to that

described by Kawauchi et al. in NK cells also exists in DU145 prostate cancer
cells [70]. To the best of our knowledge, this is the first report of an hTERTmTOR-RAPTOR complex in cancer cells implicating the involvement of mTOR in
controlling telomerase activity.
We previously demonstrated that perillyl alcohol or rapamycin individually
inhibited telomerase activity and decreased hTERT protein levels (Chapter 2).
We did, however, note discordance between the almost complete abrogation of
telomerase activity and the moderate decrease in protein levels.

Under our

standard treatment conditions, both compounds down-regulated telomerase
activity by greater than 90% (Chapter 2). Our previous results also noted that
rapamycin decreased hTERT protein levels more effectively than did perillyl
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alcohol: a 76% reduction versus a 40% loss, respectively. Such findings led us
to explore alternative post-translational regulation, i.e., the destabilization of a
multi-protein complex.
In the current study we demonstrate that treatment with either perillyl
alcohol or rapamycin at short incubation times and biologically relevant
concentrations disrupts this complex.

Perillyl alcohol was as effective as

rapamycin at dislodging hTERT from the hTERT-mTOR-RAPTOR complex. The
smaller structure and lipophilic nature of perillyl alcohol might facilitate its
diffusion into the complex and cause disruption of critical hydrophobic
interactions. Based on our results, we propose that the ability of perillyl alcohol
or rapamycin to perturb the functional hTERT-mTOR-RAPTOR complex helps
resolve the variance noted between telomerase activity and hTERT protein loss
in our previous study (Chapter 2).
Surprisingly, both losses and gains in RAPTOR-associated proteins were
detected by silver stained gel analysis after perillyl alcohol or rapamycin
treatment.

We anticipated that either agent would destabilize the complex;

therefore decreases in ~160 kDa (A) and 75 kDa (C) proteins after treatment
supported our hypothesis (Fig. 14). However, analysis of the silver-stained gel
also revealed the addition of a ~60 kDa (D) protein after treatment with either
agent (Fig. 14). Further, perillyl alcohol caused the association of ~100 kDa (B)
protein (Fig. 14). Although future studies are needed to identify these proteins by
mass spectrometry, we believe the proteins are likely telomerase inhibitors that
associate with RAPTOR post-treatment.
Others

have

reported

drug-mediated

disruption

of

protein-protein

interactions between proteins in the hTERT-mTOR-RAPTOR complex; however
we are the first to indicate complete dissociation of the multi-protein complex by
either a simple phytochemical-perillyl alcohol-or rapamycin. In separate studies,
rapamycin and curcumin were found to interrupt the mTOR-RAPTOR interaction
[139, 208], Geldanamycin-a Hsp90 inhibitor-not only displaced Hsp90 from
RAPTOR [204], but additionally dislodged hTERT from Hsp90 leading to hTERT
degradation [74], Rapamycin and geldanamycin are both polyketide macrocyclic
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antibiotics from S. hygroscopicus known to compromise protein-protein
interactions [209].

Importantly, rapamycin inhibits Hsp90 complexes through

modulation of the immunophilins FKBP52/54 [209]. These immunophilins are in
the same family as the binding partner of rapamycin, FKBP12. The rapamycinFKBP12 complex dissociates mTOR from RAPTOR by binding a hydrophobic
pocket on the mTOR surface [206, 210], Perillyl alcohol-a lipophilic compoundlikely utilizes a similar mechanism to destabilize the hTERT-mTOR-RAPTOR
complex.
Based on the RAPTOR and mTOR co-immunoprecipitation results reported
in this study, as well as previous reports of known protein interactions, we
developed a schematic representation of the hTERT-mTOR-RAPTOR complex
(Fig. 17) [70, 139, 201-205, 211]. In the diagram, RAPTOR nucleates a complex
among 4E-BP1, S6K, mTOR, hTERT, Akt, and Hsp90. Although Yip et al. report
mTORCI as an obligate dimer necessary for mTOR enzymatic activity, we have
represented the hTERT-mTOR-RAPTOR complex as monomeric for clarity [109,
206]. RAPTOR serves as the scaffold that allows mTOR to phosphorylate its
downstream targets-S6K and 4E-BP1-by physically binding them through a TOS
motif [207], thus bringing them in close proximity to mTOR [201, 202, 204], Other
studies report that Hsp90 forms a physical complex with RAPTOR and is
necessary for the mTORCI functions of the complex, serving as another
stabilizing scaffold [203, 204], Additionally, Akt, an upstream effector of mTOR,
was found in a physical complex with mTOR, supporting the idea that kinases
must physically interact with their substrates [212]. Similarly, Akt phosphorylates
TERT, and therefore, their presence together in the complex is not surprising
[61]. TERT requires interaction with both Hsp90 and Akt-which also interact with
each other-for efficient telomerase activity [70, 211, 213]. Hsp90 promotes and
maintains large protein complexes, such as the proposed hTERT-mTORRAPTOR complex [214]. Thus placement of each protein within the diagram was
based upon our results and previous reports of protein-protein interactions (Fig.
17) [70, 139, 201-205, 211]. As discussed earlier, rapamycin-and by inference
perillyl alcohol-destabilizes both of the scaffolds-Hsp90 and RAPTOR- present
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in the complex. Within this context, our results clearly show that rapamycin and
perillyl alcohol cause dissociation of the hTERT-mTOR-RAPTOR complex,
possibly providing a mechanism of action by which these agents decrease
telomerase activity in prostate cancer cells.
In addition to enabling protein kinase activities, we venture that this large
multiprotein complex has still more purposes. We further hypothesize that the
physical interaction between mTOR and TERT is necessary for cancer cell
survival [215],

By usurping the mTOR pathway, the cell may evade two

impediments to long term survival. Constitutively active mTOR in the hTERTmTOR-RAPTOR complex may stimulate TERT to ensure cancer cell immortality.
An alternative potential role for the hTERT-mTOR-RAPTOR complex is to enable
additional hTERT cellular functions, primarily DNA repair [84, 85].

Evidence

supporting this premise is the discovery by Yip et al. that the dimeric mTORCI
complex has a central cavity large enough to accommodate double-stranded
DNA [206]. Furthermore, mTOR is a member of the PIKK family, several of
which mediate DNA repair [216].
Understanding the elaborate interplay among proteins that form this
complex has established further regulation of the telomerase enzyme by the
mTOR pathway.

Agents that disrupt protein-protein interactions represent a

novel class of telomerase inhibitors and potential therapeutics [217],

We

propose that perillyl alcohol and rapamycin inhibit telomerase activity through
unique synergistic decreases of hTERT protein translation and disruption of the
hTERT-mTOR-RAPTOR protein complex.

These findings strengthen the

argument for use of perillyl alcohol as a potent cancer chemopreventive.
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CHAPTER IV
EIF4E OVER-EXPRESSION IMPARTS PERILLYL ALCOHOL AND
RAPAMYCIN-MEDIATED REGULATION OF TERT

INTRODUCTION
Gene expression is tightly regulated by both transcriptional and translational
processes. Although transcriptional control has long been touted as the principle
regulator of gene expression, it is now clear that cells depend on translational
regulation for rapid changes in protein levels. In eukaryotes, translational gene
control is mediated mainly at the rate-limiting step of initiation [218]. Translation
initiation is governed by a protein complex known collectively as elF4F
(eukaryotic initiation factor 4F) that includes elF4A-a known RNA helicase,
elF4G-a scaffold protein, and elF4E-the rate-limiting cap-binding protein [219],
Together, the proteins that comprise elF4F ensure that secondary structure in
the 5'-UTR (untranslated region) of mRNA is unwound to allow initiation of
protein translation [112].
Not all mRNA sequences are able to compete equally for available elF4E.
mRNAs with 5'-UTRs that are G-C rich have substantial secondary structure that
attenuates initiation of translation. Consequently, greater elF4E levels are
required to form the cap-binding complex, elF4F, which unfolds secondary
structure and permits efficient cap-dependent translation. mRNAs with extensive
secondary structure are generally not translated in the presence of low cellular
elF4E levels, but instead are activated with mitogens through the mTOR pathway
[115-117],

Additionally, elevated elF4E levels associated with tumorigenesis

have been shown to increase the translation of many oncogenic proteins. Free
elF4E levels are therefore tightly regulated through mitogenic activation of the
mTOR signal transduction pathway [118].
Regulation of the rate of cap-dependent translation is mediated through the
PI3K/Akt/mTOR pathway [99]. Under quiescent conditions, elF4E is sequestered
by 4E-BP1 in a configuration that prevents elF4E from partaking in translation
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initiation. Upon growth factor stimulation, a kinase cascade is activated that
results in mTOR phosphorylating 4E-BP1, which causes elF4E to dissociate
[220]. Conversely, when cells encounter stressors that inhibit mTOR signaling,
this cellular pathway ensures that proteins typically synthesized by capdependent translation are not generated. Not unlike many important pathways in
the cell, mTOR signaling and therefore cap-dependent translation is frequently
aberrant in cancer cells and is a leading target for anti-cancer therapies [218].
Treatment of cancer cells with the canonical mTOR inhibitor-rapamycin-causes
decreased 4E-BP1 phosphorylation, therefore reducing the level of free elF4E for
translation initiation [142].

Additionally, our laboratory found that plant-derived

compounds such as perillyl alcohol or genistein affect protein translation in
cultured prostate cancer cells by modulating mTOR signaling [145], specifically
both compounds decrease 4E-BP1 phosphorylation. Perillyl alcohol also disrupts
the elF4F 5'- cap-binding complex by suppressing interaction of elF4E with
elF4G.
elF4E is overexpressed in almost all cancers including carcinomas of the
prostate, breast, lung, bladder, cervical, and head and neck [118].

elF4E

overexpression not only leads to many of the phenotypic changes associated
with cancer cells including rapid proliferation, decreased apoptosis, and
malignant transformation, it is also associated with a poor prognosis in human
cancer patients [118, 221], Most cancer cells are also characterized by a de
repression of telomerase, a ribonucleoprotein responsible for elongating
telomeres

by

the addition of

hexameric

repeats that cause cellular

immortalization [36], Similar to elF4E, hTERT, the rate limiting enzymatic portion
of telomerase, is re-activated as an early and critical event in tumor cells.
Importantly, we previously observed that perillyl alcohol or rapamycin
treatment of prostate cancer cells was associated with a significant and rapid
loss of telomerase activity concomitant with a decrease in hTERT protein levels
(Chapter 2).

This finding strongly suggests that TERT protein levels and

telomerase activity are mediated in part by the mTOR pathway, the master
regulator of elF4E. The above telomerase-mTOR regulatory phenomenon was
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observed in tumor cells that endogenously over-express elF4E.

Here we

examined the mTOR contribution to telomerase activity in an immortalized nontumorigenic mammalian cell line with forced expression of elF4E. The distinction
between a cancer cell with elevated elF4E and a normal immortalized cell with
forced elF4E expression will allow us to tease apart the elF4E effects on
telomerase activity versus those that may be mediated by other oncogenic
pathways.

MATERIALS AND METHODS
Cell Lines and Cell Culture
Chinese hamster ovary (CHO)-derived cell lines (rb4E and pMV7) were
maintained at 37°C in a humidified incubator with 5% C02 in MEM medium
supplemented

with 10%

fetal bovine

serum,

1X

glutamine

and

1X

penicillin/streptomycin. Growth medium was changed weekly.

Geneticin Selection
CHO cells permanently transfected with the vector pMV7-elF4E containing
the cDNA sequence for murine elF4E under the regulation of a thymidine kinase
promoter and a neomycin (neo) resistance gene or transfected with an empty
vector (pMV7-neo) were created previously by Buechler and Peffley [144] and
designated rb4E and pMV7, respectively. Vectors were originally provided by
Nahum Sonenberg. Prior to initiating experiments, both cell lines were selected in
geneticin (G-418) (Gibco/lnvitrogen, Carlsbad, CA) according to manufacturer's
suggestions to verify the presence of vectors.

Briefly, a stock solution of

geneticin was made by dissolving it in PBS at a concentration of 50 mg/mL and
then sterile filtering. pMV7, rb4E, and control non-transfected cells were plated
at 1 X 106 in a 25 cm2 flask with 10 mL of MEM media supplemented with 10%
FBS. After an overnight incubation, geneticin was added to a final concentration
of 0.4 mg/mL. Media was replaced at least weekly and supplemented with
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geneticin for an additional 3 weeks to ensure only transfected cells would
survive.

Drug treatments
Perillyl alcohol (96% stock, Sigma-Aldrich, St. Louis, MO) was prepared in
100% ethanol; rapamycin (stock 100 pM, Cell Signaling Technology, Danvers,
MA) was dissolved in 100% DMSO [145]. pMV7 and rb4E cells were plated at a
concentration of 5x10s cells per 60 mm plate in 3 mL medium and allowed to
attach overnight. Cells were then treated with one of the following: 400 pM
perillyl alcohol for 16 hr, 10 nM rapamycin for 4 hr, or 0.1% ethanol for 16 hr as
described by Peffley et al. [145], Concentrations used of either compound are
those that can be achieved in cancer patient plasma [143, 159].

Protein Extraction for Telomerase Activity
Cells were plated at a concentration of 1x106 cells per 60 mm plate in 3 mL
medium. Cells were harvested using trypsin-EDTA (ethylenediaminetetraacetic
acid) and then pelleted by centrifugation (500 x g) for 8 min. Cell pellets were
washed with ice cold phosphate-buffered saline (PBS) and subsequently
centrifuged again. Protein lysates were obtained by resuspending pMV7 or rb4E
cells in 200 pL of ice cold 1X CHAPS lysis buffer per 1 x 106 cells. The CHAPS
lysis method was modified from that presented in Hou et al. and others [176179],

CHAPS

lysis

buffer

consisted

of

0.5%

3-[(3-

Cholamidopropyl)dimethylammonio]-l-propanesulfonic acid (CHAPS), 10 mM
Tris-HCI, pH 7.5, 1 mM MgCI2, 1 mM ethylene glycol tetraacetic acid (EGTA),
and 10% glycerol. RNase inhibitor (New England Biolabs, Beverly, MA) (final
concentration of 10 units/mL) and R-mercaptoethanol (BME) (Sigma-Aldrich, final
concentration of 5 mM) were added just prior to use. Cell lysates were incubated
at 4°C for 30 min and then centrifuged at 12000 x g for 30 min at 4°C. The
supernatant was collected, protein concentration was interpolated using a
Bradford assay and extracts were stored at -86°C.
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RTQ-TRAP Assay
Telomerase activity was detected by performing RTQ-TRAP as derived from
a protocol described by Hou et al. [178], In detail, each 25 |JL RTQ-TRAP
reaction contained: 1X SYBR Green Master mix (50 mM KCI, 20 mM Tris-HCI,
pH 8.4, 0.2 mM each dNTP, 3 mM MgCI2, iTaq DNA polymerase at 0.05 units/pL)
(Bio-Rad, Richmond, CA), 10 mM EGTA, 0.2 pg T4 gene protein (New England
Biolabs), 0.35 \iM TS primer (5-AATCCGTCGAGCAGAGTT-3') (Tm 53.6°C) and
0.35 pM ACX primer [5'-GCGCGG(CTTACC)3 CTAACC-3] (Tm 66.4°C) [180],
and 2.5 pg of protein extract. Primers were purchased from Integrated DNA
Technology (IDT, Coralville, IA). All samples were analyzed in duplicate in a 96well plate on a Bio-Rad CFX96 thermal cycler, and 1X CHAPS buffer was
included as a negative control. Reactions were incubated at 25°C for 20 min to
allow for elongation of the TS primer by cellular telomerase. The PCR protocol
began with a 95°C hot start to activate Taq polymerase, followed by 40 cycles at
95°C for 20 s, 50°C for 30 s, 72°C for 90 s [178], ending with a melt curve
protocol. Telomerase activity was comparatively assessed based on threshold
cycles (CT) [178], CT values greater than 35 were considered false positives due
to primer dimers. Experiments were conducted at least three times. Inhibition of
telomerase activity was determined as follows:

(CT treatment) - (CT control) = ACJ

(1 / 24CT) X 100 = % ACTIVITY REMAINING

RNA extraction and quantification
Total cellular RNA was isolated using PureZOL™ (Bio-Rad) according to the
manufacturer's protocol.

RNase-free-DNase I digestion (50 units) (Roche

Applied Science, Indianapolis, IN) was also performed. RNA quantification was
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determined by UV absorbance on a BioPhotometer Plus (Eppendorf®, Hamburg,
Germany).

TERT mRNA Levels
Expression of TERT mRNA was detected using real-time RT-PCR. One pg
of purified cellular RNA from untreated and treated cells was reverse transcribed
into cDNA using iScript (Bio-Rad) at 42°C for 30 min in the presence of random
hexamers and oligo(dT), Moloney murine leukemia virus reverse transcriptase
and RNasin.

Additionally, minus reverse transcriptase and a minus RNA

template reactions were included as negative controls. Analysis of TERT mRNA
expression was performed by real-time PCR amplification using a Bio-Rad
CFX96 thermal cycler.

The complete Chinese hamster (Cricetulus griseus)

TERT sequence is not defined, therefore the Chinese hamster shotgun sequence
(AFTD01128649.1) was aligned with the known Golden hamster (Mesocricetus
auratus) telomerase catalytic subunit (accession number AF149012).

PCR

primer sets for Chinese hamster TERT and an internal control gene p-actin
sequence (Cricetulus griseus beta actin [ACTB], accession number U20114)
were optimized using Beacon Designer software (PREMIER Biosoft International,
Palo Alto, CA). PCR efficiencies for each primer set were determined in triplicate
by a dilution series of the cDNA template. A master mix contained 1X SsoFast
EvaGreen (Bio-Rad), 0.5 pM of each forward and reverse primer, and 1.5 pi of
cDNA per reaction.
A

129-bp

hamster

TERT

amplicon

was

generated

using

5'-

AGCATCATCTCCAACATAGC-3' (Tm 52.3°C) and 5'-TCGGTAGCAGACCAAC3' (Tm 52.2°C). A 185-bp hamster p-actin gene amplicon was generated using
5'-GCACCACACCTTCTACAAC-3'

(Tm

52.9°C)

and

5'-

TACGACCAGAGGCATACAG-3' (Tm 52.7°C). The real-time PCR program used
was 95°C for 30 s, followed by 35 cycles at 98°C for 30 s, 65°C for 30 s, ending
with a melt curve analysis step where the temperature was reduced to 65°C, then

increased to 95°C in 0.2°C increments every 5 s. The AACT method was used to
comparatively analyze the data as described in Livak and Schmittgen [182].

Protein extraction and immunoblotting
The protocol described by Peffley et al. [145] was used with minor changes.
Briefly, cells were plated at 3x106 per 100 mm culture dish and allowed to attach
for 24 hr before treating with perillyl alcohol or rapamycin as above. Cells were
lysed in 250 pL RIPA lysis buffer containing fresh 1X Complete protease inhibitor
cocktail (Roche Applied Science), 1 mM Na3V04 and 1 mM NaF, and protein
concentrations were determined by a Bradford assay.

Protein levels were

assessed by western blotting according to [145] with some modifications. Fifty pg
total protein per well were loaded on a 4-15% polyacrylamide TGX mini-gel (BioRad) and resolved by electrophoresis in 1X Tris-glycine-SDS (0.025 M Tris,
0.192 M glycine, 0.1% SDS, pH 8.3) for 30 min at 200 volts. For western blots,
Precision Plus protein standards (Bio-Rad) (chemiluminescence) or Odyssey®
two-color protein molecular weight markers (infrared) were included to determine
protein sizes.

Electrophoretic transfer onto polyvinylidene fluoride (PVDF)

membrane was performed in 1X Tris-glycine buffer.
Membranes were stained with Ponceau red to verify protein transfer and
loading. Membranes were blocked in protein-free blok-CH™ buffer (Millipore,
Temecula, CA) for 1 hr at room temperature and then incubated with gentle
rocking in one or more of the following primary antibodies: mouse monoclonal
anti-elF4E (1:250, clone P2, Santa Cruz Biotechnology, Inc., Santa Cruz, CA),
rabbit polyclonal elF4E (1:4,000, Cell Signaling, Danvers, MA), rabbit polyclonal
anti-actin (1:500, clone H-300, Santa Cruz Biotechnology, Inc.), rabbit polyclonal
anti-p70 S6 Kinase (1:1,000, Cell Signaling), rabbit monoclonal anti-phospho-p70
S6 Kinase (Thr389) (1:1,000, clone 108D2, Cell Signaling), rabbit polyclonal antiAkt (1:1,000, Cell Signaling), rabbit monoclonal anti-phospho-Akt (Ser473)
(1:1,000, clone 193H12, Cell Signaling), rabbit polyclonal anti-4E-BP1 (1:1,000,
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Cell Signaling), rabbit polyclonal anti-phospho-4E-BP1(Thr37/46) (1:1,000, clone
236B4, Cell Signaling) and/or rabbit monoclonal anti-hTERT (1:1000; clone
Y182, Millipore) that also recognizes hamster TERT. All antibodies recognize the
rodent form of their respective protein and were diluted in blok-CH™.
Incubations were conducted overnight at 4"C and followed by extensive
washes in 1X Tris-buffered saline (TBS)-Tween 20 (0.02M Tris, pH 7.4, 0.15 M
NaCI, 0.05% Tween 20). Membranes were incubated with HRP-conjugated
secondary antibodies (goat anti-rabbit or goat anti-mouse [Santa Cruz
Biotechnology, Inc.]) were diluted 1:5000 in bl0k-CH™ buffer for 1 hr at room
temperature along with 1 pl_ StrepTactin-HRP (Bio-Rad) per 10 mL solution to
visualize Precision Plus protein standards (Bio-Rad). Subsequent membrane
washes were as described [145] and then blots were incubated for 5 min in
Immun-Star™ HRP detection system (Bio-Rad) before capturing images on a
Kodak Image Station. Densitometric analysis of protein bands was conducted
using

Kodak

Molecular

Imaging

Software

version 4.0.4.

Alternatively,

membranes were incubated with IR-conjugated secondary antibodies (goat antirabbit [IRDye 680LT] or goat anti-mouse [IRDye 800 CW] diluted 1:10000 in
blok-CH™ buffer) and incubated for 1 hr at room temperature.

Subsequent

membrane washes were as described [145] and then blots were washed for 5
min in PBS before capturing images on an Odyssey Infrared Imaging System
(Licor®). Band intensities for proteins of interest were compared relative to the
levels of actin or elF4E, which do not change in response to the above
treatments and provide a control for loading and transfer onto PVDF membranes.

Statistical analysis
All experiments were conducted three to five times with sub-sampling of
each independent quantitative experiment. Data are expressed as a mean +/standard deviation. Data were analyzed using Model I ANOVAs with SPSS
version 19.0. The relationship of interest was perillyl alcohol versus control and
rapamycin versus control; therefore, Dunnett's test was used as a follow-up to
determine statistical significance of the results.
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RESULTS
Telomerase inhibition by perillyl alcohol or rapamycin is dependent on elF4E
overexpression in immortalized CHO cells
Telomerase expression is necessary to extend telomeres found at
chromosome ends to compensate for the loss of telomeric DNA that would lead
to cellular senescence. In general, somatic cells and normal cells in culture do
not have active telomerase. In contrast, most cancer cells and cultured cells that
survive 'crisis' and become immortalized, such as CHO, have de-repressed the
enzyme by either transcriptional or post-transcriptional mechanisms [13, 36,
222],

We previously established that perillyl alcohol and rapamycin at

pharmacologically relevant concentrations (400 pM perillyl alcohol for 16 hr, 10
nM rapamycin for 4 hr), attenuated telomerase activity by over 90% in DU145
prostate cancer cells, signifying a link between mTOR signaling and telomerase
regulation (Chapter 2).

Here we performed RTQ-TRAP on protein extracts

obtained from rb4E and pMV7 cells first, to assess the effect of elF4Eoverexpression on telomerase activity, and secondly, to identify if elF4Eoverexpression modulates the regulation of telomerase activity in response to
either perillyl alcohol or rapamycin under the above standard treatment
conditions.
Basal levels of telomerase activity based upon real time PCR CT values
resulted in Ct values of 24.13 +/- 0.794 SD for rb4E and 24.34 +/- 1.518 SD for
pMV7 cells. Statistical analysis demonstrated no significant differences between
rb4E and pMV7 cells (df=2; F=0.044; p=0.845). Surprisingly however, we found
that in the absence of elF4E overexpression, telomerase activity in pMV7 cells
was unaffected by either perillyl alcohol or rapamycin (df=2; F=1.705; p=0.259)
(Fig. 18). A Dunnett's test further revealed that the slight changes in telomerase
activity in perillyl alcohol-treated (p=0.749) and rapamycin-treated samples
(p=0.446) were insignificant as compared to the control. In contrast, in elF4Eoverexpressing rb4E cells, telomerase activity was dramatically attenuated by
perillyl alcohol or rapamycin treatment, with 67% and 89% reductions,
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Fig. 18. Telomerase activity is reduced in rb4E cells in response to perillyl
alcohol or rapamycin, however pMV7 cells are unaffected. RTQ-TRAP was
used to assess the effects of perillyl alcohol or rapamycin on telomerase
activity in both rb4E and pMV7. Cells were treated with one of the following:
400 pM perillyl alcohol for 16 hr, 10 nM rapamycin for 4 hr or 0.1% ethanol
for 16 hr before lysis in CHAPS buffer.

rb4E cellular extracts are

represented by black bars; pMV7 cell lysates are represented by white
bars.

All experiments were conducted five times.

Telomerase activity

remaining was determined as described in Methods relative to ethanol
(EtOH)-treated cells, which was set at 1 (CT value for rb4E = 24.13 +/0.794 SD ; Ct value for pMV7 = 24.34 +/- 1.518 SD). Error bars represent
+/- 1 standard deviation.

Asterisks depict significant differences from

control as determined by ANOVA.
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Fig. 19. Effects of perillyl alcohol or rapamycin on TERT mRNA levels in
rb4E and pMV7 cell lines. Treatment conditions were as described in Figure
18. TERT mRNA expression was determined based on CT values derived
from quantitative RT-PCR analysis. TERT mRNA levels were normalized to
actin expression using the delta-delta CT method and expressed as a foldchange.

Black bars represent rb4E TERT mRNA levels; white bars

represent pMV7 TERT mRNA levels.

Experiments were conducted in

triplicate; error bars represent +/- 1 standard deviation. Asterisk depicts a
significant difference from control as determined by ANOVA.

respectively (df=2; F= 34.073; p=0.001) (Fig. 18). A Dunnett's test revealed
highly significant modulation of telomerase by both perillyl alcohol (p=0.001) and
rapamycin (p<0.0005). The observed down-regulation was similar to that
identified previously in our studies with human prostate cancer cells (Chapter 2).
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Neither perillyl alcohol nor rapamycin mitigates TERT mRNA levels regardless of
elF4E overexpression
Although perillyl alcohol and rapamycin-mediated effects on telomerase
activity in rb4E cells were relatively rapid suggesting translational or posttranslational events, mRNA levels were assessed to verify that TERT
transcription was not being altered. Analysis of the delta CT values of basal
TERT mRNA levels found no significant differences between pMV7 and rb4E
cells as assessed by quantitative RT-PCR (df=2; F=0.178; p=0.688) (not shown).
Further, we found no inhibitory effect on TERT mRNA levels in response to
perillyl alcohol or rapamycin treatment in either pMV7 or rb4E cell extracts (Fig.
19). Specifically in pMV7 cells, perillyl alcohol or rapamycin had little or no effect
on TERT mRNA levels (df=2; F=1.697; p=0.261).

In rb4E cells, an ANOVA on

treatment effects demonstrated a substantial increase in TERT mRNA (df= 2;
F=186.48; p<0.0005); however, a Dunnett's test revealed perillyl alcohol did not
contribute to the upregulation of TERT mRNA (p=0.782).

Rapamycin, in

contrast, significantly enhanced TERT mRNA levels 3.7-fold in rb4E cells
(p<0.0005). However, telomerase activity was significantly down-regulated under
these conditions as observed in Figure 18.

These results clearly show that

TERT transcription was not being hindered; therefore translational processes
must be at play in attenuating telomerase activity in rb4E cells (Fig. 19).

TERT protein levels are diminished by perillyl alcohol or rapamycin only in the
presence ofelF4E overexpression
We previously reported that in DU145 prostate cancer cells, hTERT protein
levels decreased in response to perillyl alcohol or rapamycin treatment (Chapter
2). Due to the apparent elF4E-dependent inhibition of telomerase activity, we
assessed the effect of elF4E-overexpression on TERT protein modulation by
perillyl alcohol or rapamycin treatment. Despite an ~5-fold increase in elF4E
levels in rb4E cell extracts compared to that found in pMV7 extracts (df=2;
F=36.941; p=0.004), the basal levels of TERT protein in both cell lines were
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Fig. 20. TERT protein levels decrease in response to perillyl alcohol or
rapamycin in rb4E cells but not in pMV7 cells, (a) Representative western blot
analysis of whole cell lysates (50 yg of protein) resolved on a 4-15%
polyacrylamide gel in presence of SDS and transferred to PVDF membrane.
Membranes were probed with antibodies against TERT (top panel) or elF4E
(loading control, bottom panel). Lane 1: Precision Plus Protein™ WesternC™
Standards. Cells were treated as described in Figure 18. (b) Densitometric
analysis of the effects of perillyl alcohol or rapamycin on TERT protein levels
(three independent experiments). Error bars represent +/-1 standard deviation.
Asterisks depict significant differences from control as determined by ANOVA.
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Fig. 21. elF4E-overexpression alters phosphorylation of S6K, Akt, and 4EBP1 and controls the response to perillyl alcohol or rapamycin.
Representative examples of three independent experiments are shown.
Rb4E or pMV7 cells were treated with biologically relevant concentrations of
either rapamycin or perillyl alcohol as described in Fig. 18. Subsequently
protein was extracted and 50 M9 was resolved on a 4-15% polyacrylamide
gel in presence of SDS and transferred to PVDF membrane. Membrane
was immunoblotted with antibodies as indicated.

POH, perillyl alcohol;

Rapa, rapamycin, EtOH, ethanol; M, protein molecular weight markers.

virtually equivalent, therefore control bars were set to 100 (df=1; F=0.196; p=
0.681). Upon perillyl alcohol or rapamycin treatment of rb4E cells, however, a
34% and 51% decrease in TERT protein levels, respectively were found (df=2;
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F=103.485; p <0.0005) (Fig. 20 (a) and (b)). A Dunnett's test further showed that
the TERT protein responses to perillyl alcohol and rapamycin were highly
significant in rb4E cells (p<0.0005). Rapamycin significantly decreased TERT
protein levels despite the increase in mRNA levels. Multiple studies have shown
mRNA levels do not often correlate to protein levels, suggesting additional
regulatory mechanisms [223, 224].

In contrast, TERT protein levels were

completely unaffected in pMV7 cells treated with perillyl alcohol or rapamycin
(df=2; F=0.057; p=0.945) (Fig. 20 (a) and (b)).

TERT modulation by perillyl

alcohol or rapamycin is thus dependent on elF4E-overexpression.

elF4E-overexpression alters phosphorylation of S6K, Akt, and 4E-BP1 and
controls the response to perillyl alcohol or rapamycin
elF4E-overexpression activates Akt via increased phosphorylation of
Ser473 and likewise increases phosphorylation of S6 ribosomal protein in mouse
fibroblasts [116]. This suggested that greater elF4E levels in rb4E may alter the
cellular response to the mTOR pathway through a positive-feedback loop. Thus
we examined the result of elF4E-overexpression on the

levels

and

phosphorylation status of Akt (Ser473), S6K (Thr389), and 4E-BP1 (Thr37/46).
Furthermore, we addressed the effect of perillyl alcohol or rapamycin treatment
on the phosphorylation of these proteins. Although rb4E cells have less Akt
protein, the protein is more highly phosphorylated than that detected in pMV7
cells (Fig. 21). A major change in the level of Akt protein or its phosphorylation
was not detected with either perillyl alcohol or rapamycin in rb4E or pMV7 cells.
A comparison between pMV7 cells and rb4E cells revealed that rb4E cells had a
more highly phosphorylated p85 isoform of S6K.

S6K-phosphorylation (both

isoforms) was almost completely abrogated by rapamycin in rb4E cells, despite
lower levels of S6K protein compared to pMV7 cells (Fig 21). Perillyl alcohol had
a similar, but more modest effect on S6K phosphorylation in rb4E cells.
Strikingly, in pMV7 cells that do not overexpress elF4E, diminished S6K
phosphorylation was not observed with rapamycin or perillyl alcohol treatment
(Fig. 21).
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Fig. 22. A schematic representation of the positive feedback loop of elF4E
on the mTOR pathway via NBS1.

elF4E upregulation drives a positive

feedback loop on the mTOR pathway resulting in increased phosphorylation
of PDK1, Akt and p70 S6K. Nijmegen breakage syndrome (NBS1).

Both rb4E and pMV7 cells had similar levels of 4E-BP1, however rb4E cells
had a higher level of phosphorylated 4E-BP1 (center and top bands). Perillyl
alcohol did not affect the phosphorylation of 4E-BP1 in either cell line. Likewise,
pMV7 cells exhibited no altered 4E-BP1 phosphorylation upon rapamycin
treatment. Conversely, reduced phosphorylation of all isoforms of 4E-BP1 was
observed with rapamycin treatment in rb4E cells, with the 4E-BP1 isoform
represented by the center band being the most affected. These findings support
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the presence of a positive feedback loop where elevated elF4E in rb4E cells
upregulates the PI3K/Akt/mTOR pathway as depicted in Figure 22 [116].

DISCUSSION
Peffley et al. (2003) reported the first evidence that perillyl alcohol, limonene
and other isoprenoids specifically affected gene expression at the translational
level [193]. Furthermore they found that isoprenoids exerted chemopreventive
and anti-proliferative effects, in part, by suppressing cap-dependent translation
via mTOR/4E-BP1/elF4E cascade, specifically through decreased 4E-BP1
phosphorylation and disruption of the elF4F cap-binding complex [145, 193],
We recently observed that treatment of prostate cancer cells with perillyl alcohol
and rapamycin individually was associated with a rapid and significant loss of
telomerase activity and hTERT protein levels (Chapter 2). Of importance to this
study was a previous finding from our laboratory that prostate tumor cells
express levels of elF4E that are approximately five-fold greater than their normal
epithelial cell counterpart [186],
Although this is the first study to show perillyl alcohol or rapamycinmediated telomerase inhibition is dependent on elF4E, it was previously
demonstrated that tumor cells are more responsive to perillyl alcohol-mediated
growth inhibition than are non-cancer cells [170, 175]. Perillyl alcohol is relatively
non-toxic and readily available through dietary sources thus making this
compound a candidate for chemoprevention [153, 158],

Although perillyl

alcohol's mechanism of action is still not fully resolved, the current study brings
us closer to understanding how this small molecule may be useful in cancer
prevention. In the context of chemoprevention, elevated elF4E expression is a
prerequisite for both perillyl alcohol-and rapamycin-dependent telomerase
inhibition as described above (Fig. 18). elF4E is overexpressed in most cancer
cells compared to their normal counterparts [120, 225].

Additionally, elF4E

overexpression and telomerase re-expression both occur relatively early in the
carcinogenesis process [35, 120],

Consequently, only cells that overexpress
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elF4E will be responsive to telomerase modulation, validating the use of perillyl
alcohol for chemoprevention [170, 175].
The above results also indicate that TERT protein and telomerase activity
are not likely regulated via enhanced elF4E-driven cap-dependent translation
because TERT protein levels were not elevated in rb4E cells (Fig. 20). This
finding contrasts to our previous studies that examined HMG-CoA reductase
protein in rb4E, in which reductase expression was increased by 400 to 500
percent compared to control cells [144, 145], This elF4E effect on reductase
mRNA was specific and associated with only an overall 15 percent increase in
total cellular protein synthesis.

HMG-CoA reductase mRNA has extensive

secondary structure in its 5'-UTR known to be responsive to elF4E levels. In
contrast, the TERT 5'-UTR has minimal secondary structure (Sundin and
Hentosh, unpublished result), suggesting that translation of this mRNA does not
require high elF4E levels. Additionally, basal TERT mRNA levels were not
upregulated in rb4E (Fig. 19).
The increased TERT mRNA levels associated with rapamycin treatment of
rb4E cells were unexpected (Fig. 19).

This phenomenon may be due to

stabilization of TERT mRNA through inhibition of protein translation by
rapamycin.

Other translation inhibitors such as cycloheximide are often

accompanied by heightened mRNA levels attributable to mRNA stabilization and
protection imparted by ribosomal binding, as reported for autophagy-related
proteins and others [226-228]. Alternatively, elF4E has ancillary cellular roles
related to protein translation including mRNA transport and turnover involving
cytoplasmic processing-bodies (P-bodies) [219],

Mammalian P-bodies are

cellular structures enriched in 5'-3' mRNA degrading enzymes [229, 230], We
propose that rapamycin treatment interferes with TERT mRNA association with,
or transport to, the P-bodies, therefore enhancing TERT mRNA levels.
Support for this conjecture is the presence of an elF4E-binding protein-4Etransporter (4E-T) found in P-bodies that interacts with elF4E and represses
translation [230]. elF4E itself also localizes to P-bodies [230]. The 4E-T/elF4E
interaction serves as a prerequisite for targeting mRNAs to P-bodies.

In
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rapamycin-treated rb4E cells, 4E-BP1 was dephosphorylated (Fig. 21), which
causes elF4E to be sequestered. Perillyl alcohol treatment did not alter the
phosphorylation status of 4E-BP1, allowing elF4E to remain free to interact with
4E-T. We further contend that 4E-BP1/elF4E binding supersedes the binding
associations between 4E-T and elF4E [219].

TERT mRNA levels were not

altered in perillyl alcohol-treated cells likely due to the integrity of the elF4E/4E-T
complex (Fig. 19). In contrast, under rapamycin treatment, little or no TERT
mRNA would be transported to the P-bodies; its mRNA would not be targeted for
degradation triggering the elevated TERT mRNA levels observed in rb4E cells
(Fig. 19).

Despite high TERT mRNA levels, translation would likewise be

negated due to elF4E binding to 4E-BP1.
Our findings of altered TERT regulation and responses in rb4E must also be
considered in light of recent studies that describe an elF4E feedback loop in the
mTOR pathway [116] (Fig. 22). As depicted, elF4E-overexpression activates
pro-survival Akt protein via increased expression of Nijmegen breakage
syndrome 1 (NBS1) [116].

The ability of elF4E to up-regulate NBS1 is

independent of the translation initiation functions of elF4E [116]. Once initiated
by NBS1, the PI3K-Akt-PDK1 pathway instigates the downstream activation of
mTOR, therefore S6K and 4E-BP1 become phosphorylated [231-233], Upon
activation, PDK1 in turn phosphorylates S6K directly [234, 235] and PKCanother upstream activator of S6K [236, 237]. Thus elF4E activation of PI3K
causes three distinct phosphorylation events of S6K, thereby amplifying the
signaling pathway.
The redundant activation of S6K by three different proteins renders rb4E
cells especially dependent on S6K activation rather than on 4E-BP1 activation.
Consistent with this premise, our results show that the basal levels of S6K
phosphorylation are greater in rb4E cells than those in pMV7 cells (Fig. 21).
Additionally, S6K phosphorylation is dramatically curtailed by rapamycin, and
reduced by perillyl alcohol only in the presence of elF4E-overexpression (rb4E
cells) (Fig. 21).

In contrast, minimal amplification of 4E-BP1 activation was

observed because it is phosphorylated via direct mTOR signaling.

Although

83
diminished 4E-BP1 phosphorylation was detected in response to rapamycin in
rb4E cells, the reduction is not as great as we would expect considering the S6K
data. The reliance of the cell on S6K activation may make rb4E cells-and by
default TERT protein levels and telomerase activity-more sensitive to perillyl
alcohol or rapamycin-mediated S6K inhibition.
As cells transition from a normal condition to a cancerous state, elF4Eoverexpression may 're-wire' the mTOR pathway in such a way that a cell
becomes more reliant on this pathway for survival and proliferation [238-241],
Although addiction of the EGFR oncogenic signal transduction pathways
(upstream of the PI3K-Akt-mTOR pathway) has been previously described [241],
the elF4E-mTOR-TERT oncogenic dependence has not been demonstrated prior
to this work.

Weinstein and Joe emphasize that in cancer cells, a specific

oncogene (i.e., elF4E) may have a more vital and altered role in a given pathway
compared with its function in normal cells [239]. elF4E-overexpressing CHO
cells are non-tumorigenic [242], however in our study on rb4E cells, elF4Eoverexpression mimics the behavior seen in cancerous cells and has assumed a
role in TERT translation via S6K. If a cell such as rb4E becomes dependent on
this pathway because of constitutive activation through elevated elF4E
expression, mTOR inhibitors such as perillyl alcohol and rapamycin would have a
much greater effect on these cells due to a phenomenon now known as
oncogenic shock [238]. Our results support an oncogenic shock hypothesis in
that perillyl alcohol and rapamycin have no effect on phosphorylation or levels of
mTOR-associated proteins-as well as TERT-in normal pMV7 cells with low
elF4E levels (Fig. 21).

Conversely, cells over-expressing elF4E become

sensitive to their effects. Linking elF4E-overexpression to the up-regulation of
NBS1 may be one of the mechanisms by which elF4E causes the suppression of
apoptosis and enhancement of survival, a phenotype associated with cancer
cells.
Elucidating the mechanism by which perillyl alcohol specifically manifests its
effects against the mTOR pathway in cancer cells provides additional support for
its efficacy as a chemopreventive agent.

Similar-phytochemicals such as
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curcumin, found in the plant Curcuma longa [218], has also been shown to have
differential effects on protein translation in cancer cells versus normal cells [218].
Specifically, curcumin modulated cap-dependent translation more efficiently in
cancer cells than in normal cells. This sensitivity may also be related to an
activated mTOR pathway in tumor cells and account for the chemopreventive
effects of curcumin [218]. Additional studies are necessary to further define the
requirement of mTOR activation in prevention of cancer by natural products such
as perillyl alcohol and related compounds.

Likewise, our findings enhance the

current understanding of perillyl alcohol's mechanism of action and highlight the
importance of this simple isoprenoid for chemoprevention.
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CHAPTER V
CONCLUSION

Defining the mechanism of action of perillyl alcohol in mTOR-mediated
regulation of telomerase activity is essential to establish the value of perillyl
alcohol as a chemopreventive. The collective findings presented in this work are
compelling as they provide the first evidence that perillyl alcohol modulates
telomerase activity via the mTOR pathway in prostate cancer cells.

Our

hypothesis that perillyl alcohol modulates telomerase expression through
translational and/or post-translational mechanisms was supported by our
findings. We determined that telomerase activity was inhibited by perillyl alcohol
through a reduction in hTERT protein as well as a destabilization of the hTERTmTOR-RAPTOR complex.

Further, we revealed that perillyl alcohol or

rapamycin-mediated inhibition of telomerase activity is dependent on elF4Eoverexpression.
We have uncovered many novel insights into telomerase regulation.
Surprisingly, we found that overexpression of one mTOR-regulated protein
(elF4E) in a normal background, could in fact 're-wire' a cellular signaling
pathway, thereby dramatically altering the way a cell responds to a drug
(rapamycin or perillyl alcohol).

Understanding these alterations in signaling

pathways as a cell becomes cancerous will help establish new anti-cancer
targets or improve drugs for the known targets.
These results will also have clinical relevance for chemoprevention through
dietary intervention. elF4E-overexpression and telomerase activation both occur
relatively early as a cell shifts from a state of normalcy to a cancerous state,
leaving a window of opportunity to target these cells before they multiply into a
fully aggressive tumor mass. If the general population increases its consumption
of fruits and vegetables, cancer rates may be decreased due to the ability of
perillyl alcohol and other isoprenoids to dramatically curtail telomerase activity.
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Although our study has revealed a mechanism by which perillyl alcohol
inhibits telomerase activity, perplexing yet fascinating findings were encountered
that present new avenues for discovery. This self-renewal pathway that we see
repeatedly in science is our own sort of job security. The more that is discovered
about a particular pathway/protein, the more questions arise to be answered
about it. After this work, we are left questioning the function(s) of the hTERTmTOR-RAPTOR complex. We speculate that DNA repair processes may be
controlled by the complex, although further research will be necessary to confirm
this hypothesis. hTERT has been implicated in dsDNA repair. Furthermore, the
mTORCI homodimer has a central cavity large enough to accommodate dsDNA.
Additionally, mTOR is in a family of kinases (PIKKK) known for their DNA repair
abilities. Interestingly, DU145 cells, which are radio-resistant, have very high
levels of telomerase activity which would enable them to overcome radiation
induced dsDNA breaks [243],

Whatever the reason RAPTOR, 4E-BP1, S6K,

Akt, Hsp90, mTOR, and TERT were linked with one another evolutionarily, we
now know the cell has made a compromise between efficiency (i.e., pairing
kinases with their substrates) and vulnerability to being hijacked.

Both EGFR-

overexpression (upstream of the PI3K-Akt-mTOR pathway) and TERToverexpression can independently cause the cell to display nearly every hallmark
of cancer (i.e., evasion of apoptosis, unchecked cell cycle progression, sustained
cell proliferation, resistance to growth inhibition, activation of invasion and
metastasis, and induction of angiogenesis [244]). We now know how intimate
these two pathways are. An aspiring cancer cell need only usurp one pathway to
then control the cancer phenotype in a multifaceted manner.
Collectively these findings provide evidence for perillyl alcohol or rapamycin
regulation of hTERT via the mTOR pathway in the presence of elF4Eoverexpression.

Further, this work promotes the continued investigation of

isoprenoids, such as perillyl alcohol, for use as chemopreventives. Together
these results underscore the complexity of cellular responses that mediate antitumorigenic effects. Consequently, additional studies must be directed towards
establishing the efficacy of these agents in a clinical setting.
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APPENDIX A
ABBREVIATIONS
Abbreviations
4E-BP1

4E-binding protein 1

4E-T

4E-transporter

m7GpppX

7-methylguanosine triphosphate

ALT

alternative lengthening of telomeres

AMPK

5'AMP-activated protein kinase

ATM

ataxia telangiectasia mutated

ATP

adenosine triphosphate

ATR

ataxia telangiectasia and Rad3-related kinase

BME

R-mercaptoethanol

BNIP3

BCI2/adenovirus E1B 19 kDa protein-interacting protein 3

bp

base pairs

BSA

bovine serum albumin

CHAPS

3-[(3-Cholamidopropyl)dimethylammonio]-l-propanesulfonic acid

CHO

Chinese hamster ovary

C02

carbon dioxide

CR4/CR5

conserved region 4 and 5

DEPTOR

DEP-domain-containing mTOR-interacting protein

DMSO

dimethyl sulfoxide

dNTP

deoxynucleoside triphosphate

E-box

Myc/Max binding site

E6

human papillomavirus type 16 E6 oncoprotein

EDTA

ethylenediaminetetraacetic acid

EGFR

epidermal growth factor receptor

EGTA

ethylene glycol tetraacetic acid

elF

eukaryotic initiation factor

EtOH

ethanol

FKBP12

12 kDa immunophilin FK506-binding protein
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Abbreviations
GAP

GTPase activating protein

GDP

guanosine diphosphate

GTP

guanosine triphosphate

H/ACA

box H and ACA elements

HCI

hydrogen chloride

HIF-1

hypoxia-inducible factor-1

HMG-CoA

Homo sapiens 3-hydroxy-3-methylglutaryl-CoA

HRP

horseradish peroxidase

Hsp90

heat shock protein 90

hTERC

human telomerase RNA component

hTERT

human telomerase reverse transcriptase

IRS1

insulin receptor substrate 1

kb

kilobases

kDa

kilodaltons

KCI

potassium chloride

Map4k3

mitogen-activated protein kinase kinase kinase kinase 3

MgCI2

magnesium chloride

MKRN1

makorin-1

mLST8

mammalian lethal with Sec13 protein 8; also known as G0L

mSIN1

mammalian stress-activated protein kinase interacting protein

mTOR

mammalian target of rapamycin

mTORCI

mTOR complex 1

mTORC2

mTOR complex 2

Na3V04

sodium orthovanadate

NaCI

sodium chloride

NaF

sodium fluoride

neo

neomycin

NF

nuclear factor

NK

natural killer

P-bodies

processing bodies
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Abbreviations
PABP

poly-A binding protein

PAGE

polyacrylamide gel electrophoresis

PBS

phosphate-buffered saline

PDCD4

programmed cell death protein 4

PDK1

phosphoinositide-dependent protein kinase I

PI3K

phosphatidylinositide-3 kinase

PIKK

PI3K-related kinase

PKC

protein kinase C

PML

promyelocytic leukemia tumor suppressor

POT1

protector of the telomere

PP2A

protein phosphatase 2 A

PRAS40

proline-rich AKT substrate 40 kDa

PROTOR

protein observed with RICTOR

PTEN

phosphatase and tensin homolog

PVDF

polyvinylidene fluoride

Rag

Ras related GTPase

RAP1

the human ortholog of the yeast repressor/activator protein 1

RAPTOR

regulatory-associated protein of mTOR

Ras

rat sarcoma

Rheb

Ras homolog enriched in brain

RICTOR

rapamycin-insensitive companion of mTOR

ROS

reactive oxygen species

rpm

revolutions per minute

RT

reverse transcriptase

RT-PCR

reverse transcription-polymerase chain reaction

RTQ-TRAP real-time quantitative telomerase repeat amplification protocol
S6K

p70 S6 kinase

Ser

serine

SDS

sodium dodecyl sulfate

Src

sarcoma

Abbreviations
STAT

signal transducer and activator of transcription

TBE

tris-borate-EDTA

TBS

tris-buffered saline

TIN2

TRF2- and TRF1-Interacting nuclear protein 2

TPP1

formerly known as TINT1, PTOP, or PIP1

TRF 1/2

telomeric repeat binding factor 1 and 2

TSC

tuberous sclerosis

Tyr

tyrosine

ULK

Unc-51-like kinase 1

UPS

ubiquitin-26 S proteasome pathway

UTR

untranslated region
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